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ABSTRACT 
Bisphosphonates (BPs) have been used clinically as anti-
resorptive/cancer agents with confounded clinical outcomes and 
uncertain/conflicting biological understanding. This study was designed to 
evaluate the impact of clinically used anti-resorption drug alendronate (ALN) on 
cancer-bone metastasis and bone biology using novel 3D cancer-bone 
interaction model systems.   
To test the effects of ALN on the cancer-bone metastasis/interactions and 
bone biology we have utilized a novel 3D Co-cultures of live mouse neonatal 
calvarial bone organs with oral squamous cancer cells in a roller tube model 
systems (Curtin et al, 2012) in the absence and presence of ALN. These model 
systems under bone resorption and formation conditions were evaluated by 
chemical, biochemical, and histological analyses of the used media and calvarial 
bones.  At the end of 8 days, the calvarial bones co-cultured with oral cancer cell 
lines in the absence and presence of ALN were processed for histological 
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observations, TRAP and ALP enzyme activities, and neutral red staining. These 
studies were complemented by the effects of ALN on oral cancer cells under 2D 
classic cell culture conditions.  
In 3D-bone organ cultures under resorption conditions, oral cancer cells 
induce differentiation of osteoclasts and bone resorption and inclusion of ALN 
inhibited cancer-induced bone resorption. However, in both bone resorption and 
formation models the oral cancer cells colonized the bone and while treatment 
with ALN inhibits bone resorption, no effect on bone colonization was evident.  
Contrary to those under 2D cell culture conditions exposure to ALN of confluent 
and non-confluent oral cancer cells in the absence of live bone impacted oral 
cancer cells significantly in a dose dependent manner. 
Our studies using live bone organ cultures with oral cancer cells under 
specific dissociated bone remodeling stages, viz., resorption or formation only, 
revealed major and significant biological events which led to the conclusions that: 
(a) In the absence of bone in 2D cultures oral cancers are sensitive to ALN 
treatment whereas in the 3D live bone microenvironment tumors are resistant to 
ALN drug therapy, and (b) oral cancer-bone metastasis is independent of bone 
remodeling stage. 
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1. Squamous Cell Carcinoma 
1.1 Epidemiology 
Squamous cell carcinoma (SCC) is the most common intraoral 
malignancy, accounting for 94% of all oral malignancies.  In the United State it is 
the 8th most common cancer in males and 15th most common in females; its 
highest incidence rate is in middle-age males of African ancestry.  (Neville, 2008) 
 
1.2 Risk Factors of Oral Cancer 
The cause of SCC is multifactorial including both extrinsic and intrinsic 
factors.  Some of the extrinsic factors include tobacco smoke, alcohol, syphilis 
and sunlight/UV exposure.  Systemic intrinsic factors include factors such as 
malnutrition ad iron-deficiency anemia.  
1.2.1 Tobacco Smoke 
Smokers have 2-3 times greater risk of developing SCC than the non-
smoking general population.  Patients who continue to smoke after diagnosis 
have 2-6 times greater risk of developing a second primary carcinoma.  
Furthermore, people smoking a pipe or cigars have a greater risk of developing 
oral cancer than cigarette smokers and the risk increase with dosage and 
smoking duration. (Neville, 2008)   
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1.2.2 Alcohol 
Alcohol consumption in combination with tobacco smoking is a significant 
risk factor for SCC development.  This risk is dose- and time-dependent, and can 
increase a person’s risk for oral cancer by 15 times or more (Neville, 2008). 
1.2.3 Syphilis 
Tertiary stage syphilis has a strong association with the development of 
dorsal tongue SCC.  However, syphilis-associated oral cancer is rare today 
because syphilis is typically diagnosed and treated before the infection 
progresses to the tertiary stage.   
1.2.4 Radiation Exposure 
Prolonged exposure to ultraviolet radiation can increase the risk of 
developing SCC of the lips.  Furthermore, radiation therapy of the head and 
neck area can increase the risk of later development of a new primary oral 
malignancy, and this effect is dose dependent.   
1.2.5 Iron Deficiency 
Iron deficiency is associated with increased risk of SCC of the esophagus, 
oropharynx, and posterior mouth.   People who suffer from iron deficiency tend to 
have impaired cell-mediated immunity and their epithelial cells have a higher 
turnover rate which can lead to atrophic or immature mucosa.   
1.2.6 Oncogenic Viruses 
No virus has been proven to cause oral cancer, but herpes simplex 
viruses (HSVs), retroviruses, and human papilloma viruses (HPVs) have all been 
suggested to play a role in the development of SCC.  HPV subtypes 16, 18, 31, 
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and 33 are the strains that have been found to associate with dysplasia and 
SCC. (Neville, 2008) 
 
1.3 Clinical and Radiographic Features 
SCC can vary in its clinical presentation and it can present as: exophytic 
(mass forming, irregular, papillary), endophytic (depressed, ulcerated, rolled 
border of red/white mucosa), leukoplakic (white patch), erythroplakic (red patch), 
or erythroleukoplakic (red-and-white patch).   
Extraorally, SCC can be found at either upper/lower lips or the lip 
vermillion.  Almost 90% of the extraoral lesions are located on the lower lip.  
Carcinoma of the lip vermillion is usually found on people with long-term UV 
radiation exposure and is usually associated with actinic cheilosis.  SCC on the 
vermillion is typically a crusted, non-tender ulceration less than 1cm in diameter 
when discovered.  It is characterized by slow growth rate.  (Neville, 2008) 
Intraorally, the most common sites for SCC include the lateral/ventral 
surfaces of tongue (50% of intraoral cancer) and floor of the mouth (35% of 
intraoral cancer).  Other possible sites of development include the hard/soft 
palate, buccal mucosa, and gingival tissue.  If the tumor is adjacent to a tooth it 
may mimic periodontal disease or pyogenic granuloma.  (Neville, 2008) 
SCC found at the soft palate or oropharyngeal mucosa is generally greater 
in size and is usually accompanied by symptoms such as dysphagia or referred 
pain to the ear.   
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 When destruction of underlying bone is present, symptoms may be painful 
or completely painless.  Radiographically it will appear as a “moth-eaten” 
radiolucency with ill-defined margins.  (Neville, 2008) 
 
1.4  Metastasis 
Metastatic spread of oral SCC is largely through the lymphatic system to 
the ipsilateral cervical lymph nodes.  When the lymph node is affected it is 
usually firm to touch, non-tender and enlarged.  If the malignant cells have 
perforated the capsule of the lymph node then the node will feel fixed.  
Extracapsular invasion is associated with poor prognosis, increased risk of 
recurrence, distant metastasis and lower survival rate.  (Neville, 2008) 
Most common sites of SCC distant metastasis are lung, liver, and bone.  
The incidence rate of distant metastasis can range from 3.8% to 23% 
(Takahama et al, 2014).  Most distant metastases are asymptomatic and are 
discovered and diagnosed only during autopsy.  In a retrospective study 
(Carlson & Ord, 2002), 4 out of 597 patients diagnosed with SCC had vertebral 
metastases accounting for 0.7% of the series.  Each of the patients experienced 
severe pain, hypercalcemic somnolence, and flaccid paralysis of the lower 
extremities (Carlson & Ord, 2002).  Takahama et al (2013) reported a case of 
SCC with metastasis to the calvarias 1 year after initial diagnosis.  Important 
predictive factors for SCC distant metastasis include the site of the primary 
tumor (hypopharyngeal tumor has the greatest risk), advanced T/N 
classification, histological grade, and ability to achieve local regional disease 
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control (Takes et al, 2012).  Median survival rate is 8.9 months for patient with 
lung metastasis, and 1.8 month for bone metastasis (Kowalski et al, 2005).   
 
1.5 Staging 
The most commonly used staging protocol is the tumor-node-metastasis 
(TNM) system.  This protocol depends on these three clinical features: T (size of 
primary tumor in centimeters); N (involvement of local lymph nodes); and M 
(distant metastasis).  Higher the stage classification indicates a poor prognosis.   
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Figure 1 – SCC at the Lateral Border of Tongue.  An ulcerated, exophytic SCC 
of the posterior lateral border of the tongue.  Reproduced from (Neville, 2008). 
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Figure 2 – SCC at the Lower Lip Vermillion.  A SCC that manifested as a small 
crusted ulcer on the lower lip vermillion.  Reproduced from (Neville, 2008) 
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Figure 3 – Tumor-Node-Metastasis (TNM) Staging System for Oral SCC.  
Tumor (T) refers to the size of the primary tumor; Node (N) refers to presence of 
regional lymph node metastasis; and Metastasis (M) refers to the presence of 
distant metastasis.  Reproduced from (Neville, 2008) 
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Figure 4 – TNM Clinical Staging Criteria for SCC.  The staging criteria of SCC 
based on the TNM classification, and the 5-year relative survival rate for each 
stage.  Reproduced from (Neville, 2008) 
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1.6 Histopathologic Features 
SCC is characterized by invasive islands of malignant squamous epithelial 
cells with irregular extensions of epithelium through the basement membrane 
and into the sub-epithelial connective tissue.  The invading cells may extend 
deeply into the underlying adipose tissue, muscle, or bone, and destroy the 
original tissue.  Strong inflammatory responses can often be noted along with 
focal areas of necrosis.  Some of the common histologic features include 
hyperchromatic nuclei, increased nuclear-to-cytoplasmic ratio, and keratin pearls, 
which are concentrically layered keratinized cells.  The histopathologic evaluation 
of the degree to which the tumors resemble their original tissue is called grading. 
Less differentiated tumors receive higher grades.  A well-differentiated SCC that 
closely resembles its parental tissue is called low-grade, and in general it grows 
at a slower rate and tends to metastasize later in its course.   
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Figure 5 – Photomicrograph of A Well-Differentiated SCC.  Islands of 
squamous epithelium are shown invading the lamina propria.  Reproduced from 
(Neville, 2008) 
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Figure 6 – Photomicrograph of A Well-Differentiated SCC with Keratin 
Pearls. Epithelial cells with hyperchromatic nuclei (arrows) are present along 
with keratin pearl formation (star).  Reproduced from (Neville et al, 2008) 
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1.7 Treatment and Prognosis 
SCC of the vermillion is usually treated with surgical wedge resection, with 
5-year survival rates of 95%-100%.  SCC of the upper lip is less common than 
lower lip or vermillion SCC, and has 5-year survival rate of 58% (Neville, 2008). 
Treatments for intraoral SCC is dictated by the clinical stage of the 
disease, and may include radical surgical excision, radiation therapy, or a 
combination of surgery with radiation therapy. Indications for radiation therapy 
include oropharyngeal lesions, regional metastasis, and high-grade 
histopathologic features.  When local lymph nodes metastasis is suspected 
radical neck dissection can be performed.   
Chemotherapy is generally administered concurrently with radiation 
therapy or by itself as palliative therapy.  Some of the commonly used 
chemotherapy agents include platinum-containing compounds, 5-fluorouracil, 
and paclitaxel/docetaxel.   
The prognosis for SCC depends on the tumor stage; stage I and II 
patients have 53%-68% 5-year survival rates while stage III and IV patients have 
27%-41% 5-year survival rates.  Therefore, early diagnosis is important for 
improving treatment outcomes.   
 
2. Bone biology 
2.1 Bone Structure 
Bone is a mineralized connective tissue whose functions include support, 
protection, mineral storage, and hemopoiesis.  Bone can be classified as either 
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long or flat bone.  Long bones include bones of the extremities, such as femur, 
tibia, radius, ulna and humerus.  Flat bones include the skull, sternum, scapula, 
and pelvis.  All bones are composed of a dense outer compact bone and a 
central medullary cavity which is filled with red or yellow bone marrow and a 
network of trabecular bone.   
Histologically, compact bone is composed of lamellae which can be 
classified as circumferential (forming the outer and inner perimeter of bone), 
concentric (forming the osteon), and interstitial (fragments of pre-existing 
concentric lamellae that are interspersed between adjacent concentric lamellae).  
The osteon, also called the haversian system, is the basic unit of bone.  It is a 
cylinder of bone that is usually 0.2mm in diameter and 2mm in length and is 
oriented parallel to the long axis of bone.  At the center of the osteon is the 
haversian canal which houses a capillary, and adjacent haversian canals are 
interconnected by Volkmann canals that create a vascular network throughout 
compact bone. (Nanci, 2008) 
Trabecular , or spongy, bone is a network of thin plates of bone within the 
bone marrow cavity.  The bone marrow contains progenitor cells for white blood 
cells, red blood cells, and platelets and plays a role in hemopoiesis.   
The outer aspect of every compact bone is covered by the periosteum 
which is a connective tissue membrane that consists of an outer and inner layer.  
The outer layer of periosteum consists of a dense, irregular connective tissue 
and fibroblasts, while the inner layer consists of osteoprogenitor cells and 
fibroblasts.  The internal surface of compact and trabecular bone is covered by 
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the endosteum composed of loose connective tissue, osteoprogenitor cells, 
osteoblasts (OB), and occasionally osteoclasts (OC).   
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Figure 7 – Compact Bone and Trabecular Bone.  An image of the body of the 
mandible, demonstrating the outer layer of compact bone and inner network of 
trabecular bone. Reproduced from (Nanci, 2008) 
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Figure 8 – Structural Organization of Bone.  Cross-section depicting 
organizational components of bone, including circumferential lamellae, osteon, 
interstitial lamellae, Haversian canal, and Volkmann’s canal.  Reproduced from 
(Nanci, 2008) 
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2.2 Bone Composition 
2.2.1  Extracellular Composition 
The extracellular matrix of bone accounts for about 90% of the weight of 
bone. The inorganic component accounts for 65% of the dry weight of bone, 
while the organic component accounts for the other 35% (Buckwalter et al, 1996)  
The inorganic component of the extracellular matrix is composed primarily 
of hydroxyapatite (HA), which contributes to the compressive strength of bone.  
HA is a naturally occurring mineral composed of calcium, phosphate, and 
hydroxide ions with a chemical formula of Ca10(PO4)6(OH)2.  The unit cell of HA is 
hexagonal, and when stacked together they form a crystalline lattice. (Nanci, 
2008) 
Type 1 collagen produced by OB makes up 90-95% of the organic 
component of the extracellular matrix.  The remainder contains hyaluronic acid, 
as well as non-collagenous proteins such as osteocalcin, osteopontin, and bone 
sialoprotein.  Collagen fibers are composed of basic subunits called 
tropocollagen molecules which are made of two α1 and one α2 polypeptide 
chains wound into a triple helix (Bornstein, 1985). They aggregate into fibrils in a 
one-quarter stagger configuration leaving a gap between the tail of one 
tropocollagen molecule and the head of the succeeding molecule of a single row, 
Tails of tropocollagen molecules overlap the heads of tropocollagen molecules in 
adjacent rows.  This arrangement allows formation of covalent cross links which 
contributes to the bone strength.  (Nanci, 2008) 
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2.2.2 Cellular Composition 
There are at least two different cell lineages present in bone: 1) 
osteogenic cells that form and maintain bone, and 2) osteoclasts that resorb 
bone.  Osteogenic cells include osteopregenitors, osteoblasts, osteocytes, and 
bone lining cells all of which are derived from mesenchymal stem cells. OCs are 
derived from hemopoietic stem cells.  OBs, OCs and bone lining cells can be 
found on the surfaces of the bone while osteocytes are found in the interior of 
bone.  (Nanci, 2008; Buckwalter et al, 1996) 
2.2.2.1 Osteoblasts 
Osteoblasts are mononucleated cells that arise from mesenchymal stem 
cells in the axial skeleton and from ectomesenchymal stem cells in the head 
(Buckwalter et al, 1996).  Osteoblasts can be cuboidal or slightly flattened in 
shape.  They are primarily responsible for synthesizing type 1 collagen and 
noncollagenous bone matrix proteins.  Collagen molecules can assemble 
extracellularly to form fibrils, and accumulate as an uncalcified matrix called 
osteoid which will act as scaffold for the deposition of the apatite crystals.  
(Nanci, 2008) 
In addition, osteoblasts also secrete cytokines and growth factors that help 
to regulate bone formation and cellular function.  They include transforming 
growth factor β (TGF- β), platelet-derived growth factor (PDGF), and insulin-like 
growth factor (IGF-I and IGF-II), which are members of the bone morphogenic 
protein (BMP) superfamily (Fleisch, 2000).   
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Osteoblasts form a layer of cells connected by gap junctions over the 
forming surface of bone.  When bone formation ceases osteoblasts flatten 
substantially and become bone lining cells.  These inactive OBs are elongated in 
shape and contain fewer protein synthetic organelles.  Bone lining cells cover 
most of the surface of the adult skeleton and it has been postulated that by 
retaining the gap junctions they create a network that functions to control mineral 
homeostasis (Nanci, 2008). 
2.2.2.2 Osteocytes 
Osteocytes are osteoblasts that become trapped within the extracellular 
matrix during bone formation.  The number of osteocytes depends on the rate of 
bone formation.  If bone formation is rapid then more osteocytes are present per 
unit volume.  The space that the osteocyte occupies in the extracellular matrix is 
called a lacuna.  Extensions of these lacunae form canaliculi which are channels 
that house radiating osteocytic cytoplasmic processes.  Through canaliculi 
osteocytes can maintain contact with adjacent osteocytes or osteoblasts on the 
bone surface.  This mechanism enables osteocytes to sense their surrounding 
biochemical and mechanical environments and to respond to or transduce 
signals to maintain bone integrity and vitality. (Buckwalter et al, 1996). 
2.2.2.3 Osteoclasts 
Osteoclasts are multinucleated cells derived from hemopoietic stem cells.  
They are responsible for bone resorption and are often found against the bone 
surface in hollow depressions called Howship’s lacunae; morphometric 
measurement of the area of Howship’s lacunae can be used to reflect the activity 
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of osteoclasts.  Use of the electron microscope permitted discovery of several 
morphologic characteristics of osteoclast, including the “ruffled border” of the 
cellular membrane that creates a sealing zone that not only attaches osteoclasts 
to the bone surface but also creates an isolated microenvironment on the bone 
surface and cytoplasm enriched in actin, vinculin, and talin. The mechanism of 
bone resorption will be discussed in a greater detail in later section. (Nanci, 
2008) 
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Figure 9 – Photomicrograph of Mandibular Bone.  Cuboidal osteoblasts are 
noted along bone-forming surfaces.  Osteocytes are observed within the calcified 
matrix and osteoid (asterisks).  Osteoclasts are found opposite of active bone-
forming surfaces.  Reproduced from (Nanci, 2008) 
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2.3 Mechanism of Bone Formation 
 Bone formation can occur through either endochondral or 
intramembranous ossification.  In intramembranous ossification bone develops 
directly within the soft connective tissue.  This bone formation process occurs at 
the cranial vault, maxilla, and body of mandible.  The mesenchymal stem cells 
proliferate, differentiate into OB and produce the bone matrix which mineralizes 
(Nanci, 2008).   
Endochondral ossification takes place for all long bones, vertebrae, ribs, 
and at the articular extremity of the mandible and base of the skull.  It starts with 
differentiation of mesenchymal cells into chondroblasts which proliferate and 
produce a cartilage matrix containing type II and X collagen.  The cartilage matrix 
is then the template for shape and position of the future bone.  Later, 
vascularization increases within the midshaft of the diaphysis, and the 
perichondrium converts to a periosteum through the development of 
osteoprogenitor cells and osteoblasts, with OB producing a collar of bone 
through intramembranous formation.  In the middle of the cartilage, 
chondroclasts resorb the mineralized matrix making room for further vascular 
ingrowth.  The mesenchymal cells differentiate into osteoblasts and begin to 
deposit osteoid on the mineralized cartilage columns and then mineralize it.  
Bone matrix surrounds and entraps some of the osteoblasts and these become 
osteocytes.  As the developing bone grows longer, osteoclasts remove the core 
of the mineralized cartilage and expand the marrow cavity.  In the long bones of 
the extremities, a secondary invasion of blood vessels into the head of the bones 
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creates a secondary ossification center, resulting in formation of the epiphyseal 
growth plate.  Longitudinal bone growth then occurs through cell division and 
interstitial growth in the plate.  The process ceases when chondroblast stop 
proliferating and the growth plate disappears (Brighton et al, 1973).   
 
2.4 Mechanism of Bone Resorption 
Bone resorption occurs in an isolated acidic microenvironment created by 
the sealed zone between OC and the bone surface.  As OCs become active part 
of its cellular membrane becomes infolded creating a region known as the 
“ruffled border”.  Bone sialoprotein and osteopontin facilitate osteoclast adhesion 
and formation of the sealing zone.  An integrin receptor for αvβ3 on osteoclast cell 
membranes recognizes and binds to the RGD (arg-gly-asp) sequence of 
osteopontin and bone sialoprotein (Franzen et al, 1985).   
Proton pumps in the ruffled border of osteoclast pump hydrogen ions into 
the sealed zone creating an acidic microenvironment that can demineralize the 
bone surface and expose the organic matrix.  Active osteoclasts contain an 
extensive Golgi apparatus, numerous mitochondria, a rough endoplasmic 
reticulum (RER), and numerous vesicles located between the Golgi apparatus 
and resorption surface.  The enzymes acid phosphastase and proteases (i.e. 
cathepsin K, collagenases, matrix metalloproteinase) are synthesized in the 
RER, transported to the Golgi apparatus and packaged into vesicles that move to 
the ruffled border.  The vesicles then release degradative enzymes into the 
sealed zone to degrade the exposed organic matrix.  During degradation the 
25	
byproducts such as calcium and protein fragments are endocytosed at the ruffled 
border, and transported in vesicles to be released into extracellular fluid.  (Zou & 
Teitelbaum, 2010) 
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Figure 10 – Mechanism of Osteoclast Resorption.  The binding of integrin 
αvβ3 receptor to RGD protein of osteopontin leads to attachment of osteoclast to 
bone surface creating the sealing zone.  Proton pump moves hydrogen ions into 
the isolated space and secretion of cathepsin K and other proteases begin the 
bone resorption process.  Reproduced from (Ross et al, 2006) 
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2.5 Modulation of Bone Resorption 
The process of bone resorption can be modulated by stromal cells in the 
marrow and OBs through secreted molecules and direct cell-to-cell interaction.  
The signaling pathway of receptor-activated nuclear factor kappa-B (RANK) and 
its ligand (RANKL) plays a major role in controlling osteoclastogenesis.  RANKL 
is expressed on the plasma membrane of stromal cells and OB binds to RANK 
on the plasma membrane of osteoclast progenitor cells.  This interaction then 
induces the differentiation of OC progenitor cells and promotes activity of 
osteoclasts.  OB also secretes osteoprotegrin (OPG) which is a decoy of RANKL 
and interferes with OC formation by blocking the interaction between RANKL and 
RANK.   
Bone resorption is also modulated by parathyroid hormone (PTH), vitamin 
D3 (1,25(OH)2,D) and calcitonin.  PTH and vitamin D3 increase bone resorption 
by stimulating OC formation while calcitonin decreases bone resorption 
(Tatevossian 1973).  In addition, interleukins 1, 3, 6, and 11 and tumor necrosis 
factor α and β stimulate bone resorption while interleukins 4 and 13 have 
inhibitory effect on bone resorption.   
 
2.6 Bone Modeling and Remodeling 
 Bone modeling is a process through which the overall size and shape of 
bones are established, and it extends in time from embryonic bone development 
to pre-adult period of human growth.  During this phase, bone is being formed 
rapidly on the periosteal surface while being simultaneously destroyed along the 
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endosteal surface resulting in the change of shape of the bone.  Because bone 
increases in length and thickness during growth bone formation occurs at a 
greater rate than bone resorption.  This process is essential for the growth of 
bone during development as well as modulation of bone structure under different 
mechanical conditions.   
 Replacement of old bone by new bone without a change in the overall 
shape of bone is called bone remodeling.  Bone turnover continues even after 
adulthood is reached and the adult skeleton is continuously degraded and 
reformed through the coordinated and coupled action of OBs and OCs.  In a 
healthy individual the amount of bone lost is balanced by the amount of bone 
formed.  But in disease such as osteoporosis the resorption can exceeds 
formation resulting in overall loss of bone.   
 
3 Metabolic Bone Diseases 
3.1 Osteoporosis 
Osteoporosis is a metabolic bone disease characterized by low bone 
density and deterioration of the micro-architecture of bone tissue, resulting in 
bone fragility and increased risk of bone fracture (Eastell et al, 2016).  A 
quantified definition was given by a study group of the World Health 
Organization, defining the disease as being present when the bone mineral 
density (BMD) or bone mineral content (BMC) is over 2.5 standard deviations 
below the young adult reference mean (Fleisch, 2000).  Osteoporosis is 
diagnosed and assessed quantitatively by techniques that can measure bone 
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mineral density.  The most common clinical measurement uses dual X-ray 
absorptiometry (DXA).   
Osteoporosis in post-menoapusal women is mainly due to lack of 
estrogen, while in men it is possibly due to reduction in testosterone.  In post-
menopausal women both the cortical and trabecular bone become thinner with 
increased porosity while the overall chemical composition of the bone remains 
the same.  A second possible cause of osteoporosis is failure to achieve optimal 
peak bone mass during adolescence, which can be affected by malnutrition, 
calcium deficiency or lack of exercise.  As people age bone resorption gradually 
becomes greater than bone formation.  The net loss of bone will reach a point 
where the overall bone structure becomes fragile and fractures can occur. 
The mechanisms leading to bone loss in osteoporosis are still under 
investigation.  Chronic lack of dietary calcium and vitamin D deficiency due to 
lack of sun exposure may play a role in the overall bone loss.  In addition bone 
loss might be related to the general muscle atrophy that accompanies with aging, 
which can lead to decreased mechanical forces on the skeleton.  For post-
menopausal women decreased estrogen level induces formation of new basic 
multicellular unit (BMU) which increases bone remodeling and amplifies bone 
loss.   
The clinical symptoms of osteoporosis include bone fractures and related 
consequences.  For middle-aged men and women the most common site of 
fracture is the forearm while fractures in the vertebrae and hip become more 
prominent later in life.   
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Treatment protocols for osteoporosis can be divided into those that inhibit 
bone loss, and those that increase bone formation.  Estrogen replacement 
therapy has been found to be effective in inhibiting bone loss and can even lead 
to some increase in bone density but long-term therapy is required as its effect 
on bone stops after discontinuation of treatment.  BP has been found to be an 
effective treatment for osteoporosis.  BPs such as ALN, risedronate, ibandronate 
and zoledronic acid have shown to decrease bone resorption and increase bone 
density.  Treatment options for increasing bone formation include increased 
calcium and vitamin D intake and administration of parathyroid hormone (PTH).   
 
3.2 Paget’s Disease 
Paget’s disease is a bone disorder characterized by increased bone 
remodeling, bone hypertrophy and abnormal bone structure.  It is usually 
diagnosed in patients over 40 years of age and who may have a genetic 
predisposition for the disease.  The initial course of disease is marked by an 
increase in bone resorption leading to a compensatory increase in bone 
formation and consequently a positive bone balance.  The disease is often 
asymptomatic and is usually discovered during a routine x-ray or measure of 
serum alkaline phosphatase.  The most common symptoms include pain, bone 
deformity, bone fracture, and neurovascular symptoms.   
Laboratory tests may show elevated level of biochemical markers for both 
bone resorption (urinary pyridinium crosslinks) and bone formation (serum 
alkaline phosphatase).  This finding is correlated with histologic studies which 
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often show a mosaic structure of areas of resorption (large number of osteoclast) 
and bone formation (osteoblasts with increased bone matrix).   
Treatments for Paget’s disease include use of BPs or calcitonin.  
Calcitonin can decrease bone turnover, however relapses can occur after 
discontinuation of treatment.  BPs are now considered the treatment of choice for 
Paget’s disease and ALN, clodronate, etidronate, pamidronate and risedronate 
have been shown to be effective in treating Paget’s disease.  BPs can decrease 
the rate of bone resorption which can then reduce the rate of bone formation due 
to the coupling effect between the two processes.  BPs can improve the bone 
morphology as the new bone formed under BPs administration is lamellar rather 
than woven.   
 
3.3 Tumor Induced Osteolytic Bone Disease 
Osteolytic tumor-induced bone disease is a condition in which tumors of 
various origins induce bone destruction leading to bone fracture, pain, and 
hypercalcemia. Bone destruction can be induced by local invasion or by 
secretion of bone resorbing factors, such as PTH-related protein, into the 
bloodstream.   
Local bone destruction is often seen in breast and lung cancer 
metastases.   The mechanism of cancer-associated bone resorption is still not 
well understood but it appears that tumor cells can either secrete or induce other 
cells to secrete bone-resorbing cytokines, such as PTH-related protein, TGFα, 
TNFα, TNFβ, IL-1α, IL-1β, and IL-6 which can induce osteoclasts to resorb bone.  
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Localized bone resorption can lead to pathological bone fracture, pain, and 
hypercalcemia.   
Malignancies of the lung, breast, head and neck, kidney and ovary can 
also induce generalized bone destruction through systemic production and 
release of osteolytic factors such as cytokines and PTH-related protein into the 
bloodstream. 
The main focus for treatment of osteolytic tumor-induced bone disease 
includes pain, bone fracture, and serum/urinary calcium level.  Initial treatments 
of tumor-induced hypercalcemia include surgical excision of the primary tumor, 
chemotherapy, and radiation therapy. BPs are effective in preventing 
hypercalcemia when it is due to local invasion of carcinomas into bone. They are 
less effective in treating hypercalcemia caused by circulating factors produced by 
cancers outside the skeleton.  In vitro BPs can induce apoptosis of myeloma and 
other cancer cells and inhibit their proliferation (Berenson, 2011).   Further study 
is required to gain a clearer understanding of BPs’ effect on tumor cells. 
 
4 Bisphosphonates 
Pyrophosphate is a normal byproduct of the anabolic process that is 
rapidly hydrolyzed into two phosphate groups once produced.  Pyrophosphate 
has been considered to be an endogenous regulator of bone mineralization as it 
rapidly binds to bone minerals and inhibits dissolution of hydroxyapatite (Russell 
et al, 1970; Fleisch et al, 1966, Fleisch, 2000).   However, rapid degradation of 
inorganic pyrophosphate makes it difficult to utilize pyrophosphate clinically.  
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Bisphosphonates were discovered to be inorganic pyrophosphate analogues with 
similar regulatory effects on bone dissolution (Russell et al, 1970).  Instead of the 
P-O-P backbone that is seen in regular inorganic pyrophosphate, BP is 
characterized by a P-C-P central structure and a variable side chain (Coelman et 
al, 2008).  The P-C-P backbone promotes binding of BP to mineralized bone 
matrix and renders BP resistant to phosphatase activity.   
  
4.1 Chemical Features of BP 
 As mentioned previously, BP is characterized by a stable P-C-P backbone 
and can form two covalent bonds with carbon, oxygen, sulfur or nitrogen atoms.  
The P-C-P backbone is crucial to the binding of BP to mineralized bone matrix as 
an oxygen atom from each of the phosphonate groups coordinate with a divalent 
cation such as Ca2+ in a bidentate manner.  If the hydroxyl (-OH) group on the 
two phosphonate groups of the P-C-P backbone is substituted by a methyl (-CH3) 
group, BP loses its ability to bind to hydroxyapatite (Sunberg, 1991).   
The chemical properties of BP can be altered with changes in the 
composition of the two side chains attached to the carbon center.  The shorter 
side chain (R1) is responsible for the chemical characteristics and 
pharmacokinetics of BP while the longer side chain (R2) determines the mode of 
action and potency of BP.  For example, increasing the length of the alkyl side 
chain will increase BP’s potency while an incorporation of an amino (-NH2) group 
to the R2 side chain can increase BP’s antiresorptive potency up to 1000-fold 
(Schenk et al, 1986).   
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4.2 Classification of BP 
BP can be divided into a non-nitrogen containing group and a nitrogen-
containing group.  Members of both groups share the same general structure of 
P-C-P backbone; but difference in the chemical composition of the two side 
chains provides each class with a different mechanism of inhibiting OC-mediated 
bone resorption.   
 The non-nitrogen containing class includes members such as clodronate 
and etidronate and they contain relatively short R1 and R2 side chains.  The 
nitrogen containing group include members whose R2 side chain contain an 
amino (-NH2) group that is either in the terminal end of the side chain or within a 
heterocyclic ring.  Members of the nitrogen-containing group include alendronate 
(ALN), pamidronate and zoledronate.   
 
 
 (A) 
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Figure 11 – BP Structure and Classification.  (A) The difference in structure 
between inorganic pyrophosphate which has a P-O-P back bone and BP which 
has a P-C-P backbone.  The R1 side chain affect BP’s binding to hydroxyapatite 
while the R2 side chain affects BP’s potency.  (B) Members of the non-nitrogen 
containing BP include clondronate, and etidronate.  Members of the nitrogen-
containing BP include ALN, pamidronate and risedronate.  Reproduced from 
(Fan, 2007) and (Roelofs et al, 2008) 
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4.3  Mechanism of Action of Non-Nitrogen Containing BP 
Non-nitrogen containing BPs can be incorporated by aminoacyl-
tRNAsynthetase into methylene-containing analogues of adenosine triphosphate 
(ATP).  This results in an analogue of ATP such as AppCH2p which replaces the 
pyrophosphate (P-O-P) moiety of ATP with the P-C-P moiety of BP.  AppCH2p 
resembles ATP but is resistant to hydrolytic breakdown and release of 
phosphate.  As a result of the non-hydrolysable nature of the ATP analogues 
their increased intracellular concentration is likely to inhibit numerous intracellular 
metabolic enzymes that are ATP-dependent and have detrimental effect on cell 
function, including inducing apoptosis.  One of the enzymes affected is the 
adenine nucleotide translocase (ANT), which translocate ATP across the inner 
mitochondrial membranes.  Consequently, there is breakdown of the 
mitochondrial membrane potential and activation of Caspase-2 and subsequent 
caspase-mediated cleavage of MSt-1, which is an apoptosis-promoting kinase 
(Rogers et al, 2011). 
 
4.4     Mechanism of Action of Nitrogen Containing BP 
The NBPs are more potent than non-nitrogen containing BPs in inhibiting 
bone resorption and they exert their effect through a different mechanism.  
NBPs such as alendronate and pamidronate inhibited cholesterol synthesis but 
did not inhibit squalene synthase (Amin et al, 1996).  This suggested that NBPs 
inhibited farnesyl pyrophosphate synthase (FPPS), an enzyme further upstream 
in the mevalonate pathway.  (Rogers et al, 2011).  The main function of the 
38	
mevalonate pathway is the production of cholesterol as well as isoprenoid lipids 
such as farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP).  
The inhibition of FPPS leads to reduced synthesis of FPP and GGPP both of 
which are essential for post-translational (prenylation) of small GTPase such as 
Ras, Rab, and Rac, and accumulation of isopentenyl pyrophosphate (IPP), 
which is the metabolite immediate upstream of FPPS in the mevalonate 
pathway.  These small GTPase enzymes are important signaling proteins that 
regulate processes necessary for osteoclast function such as cytoskeletal 
arrangement, membrane ruffling, trafficking of intracellular vesicles and 
apoptosis (Ridley et al, 1992; Marshall 1993; Zerial et al, 1993).  IPP can be 
converted into a toxic ATP analog, ApppI, which inhibits the mitochondrial ANT 
and can cause osteoclast apoptosis.  Therefore, loss of prenylation of GTPase 
and accumulation of unprenylated proteins can lead to loss of signaling required 
for osteoclast function and inappropriate activation of downstream signaling 
pathways. 
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Figure 12 – NBP’s Effect on Mevalonate Pathway.  NBP are potent inhibitors 
of FPP Synthase preventing the synthesis of FPP and GGPP which are required 
for the prenylation of proteins that are crucial for osteoclast function and survival. 
Reproduced from (Rogers et al, 2011) 
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4.5 Bisphosphonate and Osteoclast 
The preferential binding of BP to bone matrix brings them into close 
contact with osteoclasts.  During osteoclast-mediated bone resorption the acidic 
pH in the resorption lacuna causes BP to be dissociated from the bone mineral 
surface followed by intracellular uptake of BP into osteoclast by endocytosis.  
Since other cells are not able to acidify the bone surface to release mineral-
bound BPs osteoclasts appear to be the only cell type capable of internalizing 
substantial amount of BPs in vivo (Rogers et al, 2011; Sato et al, 1991).  In vitro 
studies have shown that BPs can decrease osteoclasts’ lactic acid production, 
proton secretion, lysosomal enzyme activity, and prostaglandin synthesis 
(Fleisch, 2000) 
 
4.6     BP’s Effect on OBs 
The inhibitory effect of BP has on OC has been well-documented.  
However, there is limited detail on the effect BP has on OB.    BP has been 
shown to decrease expression of RANKL and increase expression of 
osteoprotegrin (OPG), which acts as a RANKL decoy receptor.  (Viereck et al, 
2001; Pan et al, 2004). RANKL is a protein expressed by OB and it binds to the 
RANK receptor on OC.  This interaction increases bone resorption by inducing 
the differentiation of OC progenitor cells and promotes activity of osteoclasts.  
OB also secretes osteoprotegrin (OPG) which interferes with OC formation by 
blocking the interaction between RANKL and RANK.   
Some studies have shown that BP enhances osteoblast proliferation, 
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differentiation, and bone mineralization (Tenenbaum et al, 1992; Giuliani et al, 
1998; D’Aoust et al, 2000), while other studies showed contradictory effects 
(Tsuchimoto et al, 1994; Idris et al, 2008).  At low concentrations ranging from 
10-8M to 10-9M BP stimulated osteoblast proliferation whereas concentrations 
higher than 10-6M inhibited osteoblast proliferation and differentiation (Plotkin et 
al, 1999).  ALN increased osteoblast proliferation at 5 µM but decreased 
osteoblast proliferation at concentration higher than 20 µM (Kruger et al, 2016). 
 
4.7 BP’s Effect on Bone Mineral 
BP binds strongly to bone matrix and inhibits bone resorption by inhibiting 
the dissolution of the hydroxyapatite crystals.  BP has a high affinity for the Ca2+ 
cation in hydroxyapatite crystals on the bone surface.  They are in in high 
concentration at sites of osteoclast-mediated bone resorption or areas of active 
bone turnover.  During bone formation BP becomes embedded in the bone 
matrix and becomes inactive.  But during bone resorption the acidic pH in the 
resorption lacuna causes BP to be dissociated from the bone mineral surface 
and become active.   
 
4.8 Pharmacokinetics 
4.8.1 Intestinal Absorption 
The bioavailability of BP through an oral dose is low ranging between 1 to 
10%, most likely due to its low lipophilicity and high negative charge which 
prevent paracellular transport.  Absorption of BP in the GI tract can occur in the 
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stomach as well as in the small intestine through passive diffusion.  The 
absorption is significantly diminished when BP is taken with a meal; especially in 
the presence of calcium and iron.  The decrease may be due to conversion of BP 
into a nonabsorbable form.  
4.8.2 Distribution 
Twenty to eighty percent of absorbed BP is taken up by bone and the 
remainder is rapidly excreted in urine.  The amount of deposition is proportional 
to amount of BP administered.  When large amounts of BP are given through 
rapid intravenous injection formation of insoluble complexes or aggregates may 
happen that can impair kidney function. 
The half-life of circulating BP is between 0.5-2 hours.  After uptake by 
bone BP is deposited in areas of both bone formation and bone resorption.  Once 
deposited in bone BP can be buried under new layer of bone, and is only 
released under the condition of bone resorption.  Therefore the half-life of BP 
deposited in bone depends on the rate of bone turnover and can be as long as 
10 years. 
4.8.3 Renal Clearance 
BP has high renal clearance and is actively secreted through the urinary 
system.  Decrease in urinary secretion has been noted in cases of renal failure 
and it is poorly removed through peritoneal dialysis.  Therefore the use of BP 
should be very cautious in patients with chronic kidney disease. 
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4.9 Side Effects 
Some of the common side effects associated with BP administration 
include GI tract discomfort, renal toxicity, hypocalcaemia, secondary 
hyperparathyroidism, BP-related osteonecrosis of the jaw (BRONJ), and atypical 
fractures of femoral diaphysis. Due to the long half-life BP can have in the human 
body these side effects can persist after completion of treatment.   
Oral administration of BP can be accompanied by irritation of esophagus 
and GI tract which can result in nausea, dyspepsia, vomiting, diarrhea, and 
sometimes even esophageal erosion.  These side effects might be due to the 
inhibitory effect of NBP on the mevalonate pathway which can inhibit keratinocyte 
growth.  In order to reduce the side effects it has been recommended for patients 
to sit upright for 30 minutes after ingestion, take the medication with water, or to 
discontinue the medication in the presence of symptoms (de Groen et al, 1996) 
When BP is administered through intravenous injection, caution must be 
taken to avoid administration of large amount of BP in a short period of time.  
Rapid injection of BP can lead to renal failure due to formation of insoluble 
aggregate with metal ions which cannot be filtered and are held back in the 
kidney.  (Fleisch, 2000).   
Hypocalcaemia may be observed within the first few weeks of BP 
administration due to its inhibitory effect on osteoclasts.  This is usually without 
clinical consequence but prolonged hypocalcaemia can lead to cardiac 
arrhythmia, seizure, or parathesia of the lips, mouth and limbs. Secondary 
hyperparathyroidism can sometimes be noticed as the body tries to compensate 
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for the deficiency in calcium.  Hyperplasia of the parathyroid glands may occur, 
and the excessive production of PTH would stimulate OC bone resorption, 
increase release of calcium into bloodstream, and increase tubular reabsorption 
of calcium.   
BRONJ can be defined as “an area of exposed bone in the maxillofacial 
region that does not heal within 8 weeks after identification in a patient who 
received BPT and had not received radiation therapy to the craniofacial region.” 
(Vescovi et al, 2012)  The etiology of BRONJ remains unknown but it was 
proposed that BRONJ might be caused by BP’s suppression of bone turnover 
which can inhibit bone’s ability to repair microdamages (Allen & Burr, 2009).  The 
most common sites for BRONJ to occur are the mylohyoid ridge and the 
maxillary alveolar ridge.  The development of BRONJ can be affected by the type 
of BP, length of treatment, concomitant therapy (such as chemotherapy, radiation 
treatment of the head and neck area), and systemic conditions (i.e. anemia, 
diabetes, hypercalcemia, and coagulation disorder).  Invasive dental procedures 
such as teeth extraction, dental implant placement, and dentoalveolar surgery 
can increase the risk of developing BRONJ; therefore dentists need to be 
cautious when considering such treatments for patients with history of BPT.   
Symptoms of BRONJ include non-healing area of exposed bone, 
fistulization, purulent discharge, pain, nerve paresthesia, teeth mobility, maxillary 
sinus involvement and mandibular fracture.  BRONJ can be diagnosed using 
orthopantomography, computed tomography (CT) scans, and magnetic 
45	
resonance imaging (MRI).  Histologic characteristics of BRONJ include non-vital 
bone, empty lacunae, and lack of bone remodeling. (Vescovi et al, 2012).   
Treatment options for BRONJ can be diverse including discontinuation of 
BP, surgical therapy, oxygen hyperbaric therapy, ozone application, and laser 
surgery (Vescovi et al, 2012).   
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5. Aim and Goals 
The current study evaluated and determined the interplay between 
Alendronate (Fosamax), a clinically used nitrogen-containing bisphosphonate 
(NBP), squamous cell carcinoma cells, and osteocytes/osteoblasts/osteoclasts 
using an ex-vivo three-dimensional live cancer-bone interactive model.  The 
experimental approaches were designed to determine the effect of NBP on 
osteoclastic bone resorption and osteoblastic bone formation, with or without the 
presence of oral cancer cells, using live neonatal mouse calvarial bone.  
Two model systems were used: 
(i) The resorption model used oral cancer cells-induced osteoclast 
formation and bone resorption.  (ii) The formation model used ascorbic acid-
induced osteoblast differentiation and bone formation.  Quantitative analysis for 
media calcium changes, tartrate-resistant acid phosphatase (TRAP) enzyme 
activity (which reflects osteoclast activity), and alkaline phosphatase (ALP) 
enzyme activity (which reflect osteoblast activity) and qualitative analysis by 
Neutral Red staining, histological observation and two-photon confocal-
microscopy were performed  
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6.  MATERIALS AND METHODS 
6.1  Effect of ALN on SCC2-dsRED cells 
Oral cancer cells (SCC2-dsRED) (Dr. David Sherr’s laboratory) were 
grown with DMEM in the presence of 10% Fetal Calf Serum (FCS, Sigma-
Aldrich, Co) at 37°C until confluent using 10cm culture dishes and media 
changes every 2 days.  At the start of the experiment, the cancer cells were 
rinsed with PBS and harvested using Trypsin in 10 ml of DMEM followed by 
centrifugal pelleting.  The collected cancer cells were re-suspended in 10 ml of 
DMEM and re-pelleted.  The cancer cells were then suspended in DMEM and 
total number of cells was estimated by microscopy.  2 ml of DMEM spiked with (3 
X 105) cancer cells were added to each well of a 6-well cell culture plate.  One 
control group (0 µM ALN in media) and four experimental groups (1 µM ALN, 5 
µM ALN, 15 µM ALN, 30 µM ALN in media) were included in the study.  In 
addition, the effects of FCS vs. bovine serum albumin (BSA) in cell-culture 
media, ascorbic acid (ASC) (150 µg/ml), different timing of ALN addition (seeding 
vs. confluence) on oral squamous carcinoma cells were investigated.  See Fig. 
13 for experimental design.  The experiment was carried out for 10 days and the 
cell-culture media was changed every 2 days.  At time of each media change, 
number of detached cancer cells suspended in cell culture media was counted 
using microscopic approach.  At the end of the experiment, each well was treated 
with Trypsin in 2 ml of DMEM, and the number of cancer cells attached to the 
well was counted by microscopy.   
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Experiment FCS 
in 
Media 
BSA 
in 
Media 
Ascorbic 
Acid (150 
µg/ml ) in 
Media 
Timing of 
ALN 
Addition 
ALN (0 
µM) 
ALN (1   
µM) 
ALN (5   
µM) 
ALN (15   
µM) 
ALN (30   
µM) 
1A X   Confluence X X X X X 
1B X  X Confluence X X X X X 
2A X   Seeding X X X X X 
2B X  X Seeding X X X X X 
3A  X  Confluence X X X X X 
3B  X X Confluence X X X X X 
4A  X  Seeding X X X X X 
4B  X X Seeding X X X X X 
 
Figure 13.  Summary of experimental design for 2D SCC2 .   
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6.2 Live Mouse Calvaria Bone Organ Cultures 
 Under sterile conditions, 5-8 day-old neonatal CD-1 mice calvaria (Charles 
River Laboratories, MA) were dissected and trimmed into a trapezoidal structure 
by partial removal of occipital lobe and two frontal lobes.  After dissection each 
calvarium was placed free floating in a roller tube (15 cm X 16 cm, Bellco, Inc., 
NJ) containing 2.0 ml of bone culture media under normal oxygen condition with 
or without SCC2 cells (2.5 X 105 cells per tube) in suspension, in the absence 
and presence of ALN (Sigma-Aldrich).  The live bone organ culture medium 
preparation consisted of Dulbecco’s Modified Eagle’s Medium (DMEM) with 
bovine serum album (BSA) or fetal calf serum (FCS), 100 U/ml penicillin, and 250 
ng/ml amphotericin B (Gibco, Grand Island, NY).  In addition, ASC (150 µg/ml) 
and different concentration of ALN were supplemented to the medium depending 
on the experimental designs.  Through this approach we were able to dissociate 
the process of bone resorption and bone formation involved in bone modeling.   
6.2.1  SCC2-dsRED Oral Squamous Carcinoma Cell Culture 
SCC2-dsRED oral squamous carcinoma cells (Dr. David Sherr’s 
laboratory) were grown with DMEM, in the presence of 10% Fetal Calf Serum 
(FCS, Sigma-Aldrich, Co) at 37°C until confluent using 10cm culture dishes and 
media changes every 2 days.  On the day of bone organ co-cultures with SCC2-
dsRED cells, the cancer cells were rinsed with 10 ml of bone organ culture 
media, then harvested using trypsin in 10 ml of bone culture media, followed by 
centrifugal pelleting.  The collected cancer ells were re-suspended in 10 ml of 
bone organ culture media and re-pelleted.  The cancer cells were then 
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suspended in bone organ culture media and total number of cells was counted by 
microscopy. Bone culture media 2 ml with 2.5 X 105 cancer cells were added to 
each roller tube to be co-cultured with a single full calvarial bone. 
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Figure 14.  The set up of the roller tube system.  In each roller tube one 
calvarial bone was cultured with SCC2-dsRED oral squamous carcinoma cells 
and 2 ml of culture media.  Sterile stoppers were used to seal the tubes, and the 
tubes were then placed on a roller tube apparatus with a setting of 5 revolutions 
per minute in a 37°C incubator. Reproduced from (Curtin et al, 2012) 
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• Calvaria alone, SCC2 cells alone, or calvaria with SCC2 cells were placed 
in each roller tube along with 2 ml of culture medium.   
• Sterile stoppers were used to seal the tubes, and the tubes were placed 
on a roller tube apparatus with a setting of 5 revolutions per minute in a 
37°C incubator.   
• Media was changed every 2 days under sterile condition, for a total of 8 
days. 
• On the day of media changes, medium from each tube was collected and 
aliquoted into a labeled 2 ml eppendorf tube, and stored in 4°C refrigerator 
to be used for calcium, and tartrate-resistant phosphatase (TRAP) 
analysis.   
• The cells suspended in medium were pelleted centrifugally, and then re-
suspended in 200 µl of DMEM.  The cells suspended in medium were then 
counted by microscopy.   
• On the last day of the experiment each test tube was treated with 2 ml of 
Trypsin and the number of SCC2 cells attached to the wall of the roller 
tube was counted.  
• At the conclusion of the experiment all of the calvaria were hemi-dissected 
in the mid sagittal suture:  
1. Two half calvaria from each of the experimental groups were placed in 
2 ml eppendorf tube with 1 ml of Trypsin, and placed in a 37°C 
incubator for 5 minutes.  The cells were then centrifugally pelleted and 
re-suspended in 200 µl of DMEM.  SCC2 cells that had been attached 
to the calvaria were then counted by microscopy.   
2. Two half calvaria from each group were fixed in 10% formalin, paraffin 
sectioned, and stained with hematoxylin and eosin (H&E, Boston 
Medical Center, Department of Pathology) for histological analysis.   
3. Two half calvaria from each group were stained with neutral red (NR, 
Sigma-CO) to visualize general OCs activity.   
4. Two half calvaria from each group were prepared for two-photon 
confocal-microscopy, see section 6.7 
 
Table 1 - General Experimental Procedures for 3D Roller-Tube Co-Culture.  
General experimental procedures for 3D roller-tube co-culture are outlined.  The 
procedures are applicable to both bone resorption and bone formation models.   
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6.2.2  Effect of ALN on Bone Resorption Model 
 The effect of ALN on OC and bone resorption was studied utilizing live 
mouse calvarial co-cultures with SCC2 cells. Six cultures were set up as follows: 
(a) calvaria negative control (culture medium only) (n = 7); (b) calvaria with 30 
µM ALN (Sigma-Co) (n = 4); (c) SCC2 cells negative control (culture medium 
with FCS (Sigma-Co)) (n = 7); (d) SCC2 cells negative control (culture medium 
with BSA (Sigma-Co)) (n = 3); experimental treatment of (e) calvaria + SCC2 
cells (culture medium only) (n = 7); and (f) calvaria + SCC2 cells + 30 µM ALN 
(Sigma-Co) (n = 4), Figure 15.  See Table 1 for general experimental procedures. 
6.2.2.1  Effect of ALN Concentration on Bone Resorption Model 
To further evaluate the effect of different ALN concentrations on OC and 
bone resorption, a total of three cultures were set up as follows: (a) calvaria + 
SCC2 cells + 0.5 µM ALN (single dosage) (n = 4); (b) calvaria + SCC2 cells + 0.5 
µM ALN for 8 days (Sigma-Co) (n = 4), (c) calvaria + SCC2 cells + 1.5 µM ALN 
for 8 days (Sigma-Co) (n = 4); Figure 15.  See Table 1 for general experimental 
procedures. 
6.2.3  Effect of ALN on ASC Stimulated Bone Formation Model 
 The effect of ALN on OB and bone formation was studied by utilizing live 
mouse calvarial co-cultures with SCC2 cells. Total of six cultures were set up as 
follows: (a) calvaria control with 150 µg/ml ASC (n = 3); (b) calvaria with 150 
µg/ml ASC + 30 µM ALN (Sigma-Co) (n = 4); (c) SCC2 cells control (culture 
medium with FCS + 150 µg/ml ASC) (Sigma-Co)) (n = 7); (d) SCC2 cells control 
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(culture medium with BSA + 150 µg/ml ASC) (Sigma-Co)) (n = 3); experimental 
treatment of (e) calvaria + SCC2 cells (culture medium + 150 µg/ml ASC) (n = 9); 
and (f) calvaria + SCC2 cells + 30 µM ALN + 150 µg/ml ASC (Sigma-Co) (n = 9), 
Figure 15.  See Table 1 for general experimental procedures. 
6.2.3.1  Effect of ALN Concentration on ASC Stimulated Bone 
Formation Model  
To further evaluate the effect of different ALN concentrations on OB and 
bone formation, a total of three cultures were set up as follows: (a) calvaria + 
SCC2 cells + 0.5 µM ALN (single dosage) + 150 µg/ml ASC for 8 days (n = 4); 
(b) calvaria + SCC2 cells + 0.5 µM ALN + 150 µg/ml ASC for 8 days (Sigma-Co) 
(n = 4), (c) calvaria + SCC2 cells + 1.5 µM ALN + 150 µg/ ml ASC for 8 days 
(Sigma-Co) (n = 4); Figure 15.  See Table 1 for general experimental procedures. 
6.2.4  Effect of Calvarial Cells Viability on Bone Resorption Model 
To evaluate the effect of calvarial cells viability on OC and bone 
resorption, two groups of cultures were set up as followed: (a) calvaria (freeze & 
thaw) + SCC2 cells (n = 3); (b) calvaria (treated with 10% formaldehyde) + SCC2 
cells (n = 3); Figure 15.  Calvaria in group A were placed in -4°C freezer 
overnight the night before the start of experiment.  On the day of experiment, the 
eppendorf tube was taken out of freezer and thawed at room temperature for 30 
minutes.  For group b, calvaria were treated with 10% formaldehyde prior to start 
of experiment.  See Table 1 for general experimental procedures. 
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6.2.5  Effect of Calvarial Cells Viability on ASC Stimulated Bone 
Formation Model 
To evaluate the effect of calvarial cells viability on OB and bone formation, 
two groups of cultures were set up as followed: (a) calvaria (freeze & thaw) + 
SCC2 cells + 150 µg/ml ASC (n = 3); (b) calvaria (treated with 10% 
formaldehyde) + SCC2 cells + 150 µg/ml ASC (n = 3); Figure 15.  Calvaria in 
group A were placed in -4°C freezer overnight the night before the start of 
experiment.  On the day of experiment, the eppendorf tube was taken out of 
freezer and thawed at room temperature for 30 minutes.  For group b, calvaria 
were treated with 10% formaldehyde prior to start of experiment.  See Table 1 for 
general experimental procedures. 
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Experimental Control (Calvaria) 
Media only for 8 days (n = 7) 
Ascorbic Acid (150 µg/ ml) for 8 days (n= 3) 
ALN (30 µM) for 8 days (n = 4) 
Ascorbic Acid (150 µg/ ml) & ALN (30 µM) for 8 days (n = 4) 
 
Experimental Control (SCC2 Cells) 
Media (FCS) only for 8 days (n = 7) 
Media (BSA) only for 8 days (n = 3) 
Media (FCS) & Ascorbic Acid (150 µg/ ml) for 8 days (n = 7) 
Media (BSA) & Ascorbic Acid (150 µg/ ml) for 8 days (n = 3) 
 
Resorption Model (SCC2 Cells + Calvaria) 
Media only for 8 days (n = 7) 
ALN (30 µM) for 8 days (n = 4) 
ALN (0.5 µM, 1 dosage) for 8 days (n = 4)  
ALN (0.5 µM) for 8 days (n = 4) 
ALN (1.5 µM) for 8 days (n = 4) 
Calvaria (Freeze/Thaw), Media only for 8 days, (n = 3) 
Calvaria (10% Formaldehyde), Media only for 8 days, (n = 3) 
 
Formation Model (SCC2 Cells + Calvaria) 
Ascorbic Acid (150 µg/ ml) for 8 days (n = 9) 
Ascorbic Acid (150 µg/ ml) & ALN (30 µM) for 8 days (n = 9)  
Ascorbic Acid (150 µg/ ml) & ALN (0.5 µM, 1 dosage) for 8 days (n = 4) 
Ascorbic Acid (150 µg/ ml) & ALN (0.5 µM) for 8 days (n = 4)  
Ascorbic Acid (150 µg/ ml) & ALN (1.5 µM) for 8 days (n = 4)  
Calvaria (Freeze/Thaw), Ascorbic Acid (150 µg/ ml) for 8 days (n = 3) 
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Calvaria (10% Formaldehyde), Ascorbic Acid (150 µg/ ml) for 8 days (n = 3) 
 
Figure 15 - Summary of experimental treatment groups.  Categorized by 
control groups, resorption model and formation model. 
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6.3 Observation of Global OC Activity by Neutral Red  
Neutral red has been known to be rapidly absorbed by OC cells, therefore 
neutral red staining can provide quantitative estimation of OC activity due to the 
multinucleated nature of OC cells (Curtin et al, 2012).  At the end of each 
experiment, the bisected half calvaria were stained with 70 µg/ ml NR (Sigma-
Co) then incubated under 37°C for 45 minutes.  The calvaria were then observed 
under microscope and digital images were taken.  The calvaria were then 
washed with phosphate buffered saline (PBS) before fixing in 10% formalin 
overnight.  
 
6.4 Assessment of Media Calcium Release and Uptake in Bone 
Resorption and Formation Model 
In both the bone resorption and formation models for the calvaria cultures, 
calcium release and uptake were reflected in the media respectively.  Calcium 
assays are based on the chemical reaction between calcium chelating 
chromorphoric reagent and calcium ion available in the media (Dorogi, 1984).  
The reaction forms an intense purple complex, which is reflected by the 
absorbance that is directly proportional to the calcium concentration of the media.   
6.4.1 Determination of Standard Curve for Calcium Assay 
The determination of media calcium concentration was calculated by using 
a standard curve.  Stock calcium chloride solution was made by weighing 1.8 mg 
O-Cresolphthalein complex one (Sigma-Aldrich Co.) reagent, and dissolved in 10 
ml sodium bicarbonate buffer, pH 10.8 (concentration = 50 mM).  Calcium 
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chloride (CaCl2) standards with concentrations ranging from 0-70 nmol/10µl were 
prepared.  10 µl CaCl2 standards and 190 µl O-Cresolphthalein complex one 
regent solution were loaded into 96 well plate, and absorbance value was 
obtained using Berthold Tristar LB 941 plate reader (Berthold Technologies 
GmbJ & Co. KG.) at wavelength of 590nm.  Linearity of assay and correlation 
value greater than 0.98 were achieved, see Figure 16. 
6.4.2 O-Cresolphthalein Complex One Calcium Assay 
190 µl of calcium reagents were pipetted into a 96 well plate, followed by 
addition of 10 µl of each standard and sample into its respective well.  The assay 
was carried out in duplicates.  The absorbance values were obtained with 
Berthold Tristar LB 941 plate reader (Berthold Technologies GmbJ & Co. KG.) at 
wavelength of 590nm.   
Average absorbance values were calculated for each standard and 
sample.  Background reading was adjusted by subtracting averaged blank 
standard absorbance value from the averaged sample absorbance values.  
Average standard absorbance values were plotted as a function of final calcium 
concentration to obtain the standard curve equation of y = mx.  Corrected sample 
absorbance values were plotted to calculate the final calcium concentration.  
Sample dilution factor was taken into account by multiplying the final calcium 
concentration with 0.1 to obtain units of µM/ ml.  The data produced reflect 
calcium release or uptake at each collection time point.  Using Microsoft Excel 
the date were plotted as a function of time and cumulative calcium release or 
uptake graphs.   
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Figure 16 – Example of Actual Standard Curve Used.  Experimental standard 
curve plotted after background correction to be used in the calculation of calcium 
concentration.  The absorbance values were obtained with Berthold Tristar LB 
941 plate reader (Berthold Technologies GmbJ & Co. KG.) at wavelength of 
590nm.   
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6.5 Assessment of OC with TRAP Activity 
During bone resorption, TRAP is highly expressed by OC, therefore it is 
an ideal marker for OC activity level.  The TRAP assay utilizes the inhibitory 
effect of tartrate on non-TRAP to isolate the TRAP activity, and the OC activity is 
determined utilizing p-nitrophenyphosphate (p-NPP) as a chromogenic substrate 
in the assay.  TRAP dephosphorylates p-NPP producing p-nitrophenol (p-NP) 
which under alkaline condition deprotonates the phenolic (-OH) group producing 
a bright yellow color that can be measured by ultraviolet and visible light 
spectrophotometry.   
The TRAP reagent buffer, pH 4.8, consisted of 0.1 M Sodium Acetate 
(C2H3NaO2), 50 mM Tartaric Acid (C4H6O6), 16 mM p-NPP (Sigma-Aldrich, Co.), 
1 mM Zinc Chloride (ZnCl2).  The assay was carried out in duplicate and TRAP 
activity was measured by incubating 50 µl medium of each sample with 250 µl of 
the TRAP reagent buffer in each well of a 96 well plate for 30 minutes at 37°C.  
At the end of the incubation time 10 µl of 1M NaOH was added to each well to 
stop the reaction, and absorbance measured at a wavelength of 410nm with 
Genius Detector as described in (Curtin et al, 2012).   
 
6.6 Assessment of OB with ALP Activity 
ALP was used as a marker for OB activity in the formation model.  The 
ALP assay utilized p-NPP as a chromogenic agent.  The ALP reagent buffer, pH 
7.8, consisted of 0.15 M sodium chloride (NaCl), 30 mM sodium bicarbonate 
(NaHCO3), 16 mM p-NPP.  The assay was carried out in duplicate and ALP 
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activity was measured by incubating 50 µl medium of each sample with 250 µl of 
the ALP reagent buffer in each well of a 96 well plate for 30 minutes at 37°C.  
After incubating, absorbance was measured at a wavelength of 405nm with 
Genius detector as described in (Wang et al, 1998).   
6.6.1 TRAP and ALP Calculation 
The absorbance measurements for both TRAP and ALP assays were 
calculated by subtracting the average background absorbance.  Concentration of 
p-NP was calculated with adjusted measured absorbance using Beer-Lambert 
law equation, c = Aλ / (ελX l).  Using the molar absorptivity constant (ε405) of 
12,500 (mol/L)-1cm-1 and a path length (1) of 1cm.  Incubation time of 30 minutes 
was used to calculate the rate of substrate hydrolysis in units of mol/L*min.  The 
final enzyme activity is expressed in unit of µMol/L*min. 
 
6.7 Histology Preparations 
Histological observations were obtained from 2 bisected half calvaria of 
each treatment group.  All digital images of H & E stained sections were captured 
under 10X magnification with a`compound microscope (Nikon), by Retiga 1300 
digital camera (Qimaging, Canada).   
 
6.8 High-Resolution Two-Photon Confocal-Microscopy 
High-resolution two-photon confocal miscopy was performed on two 
bisected half calvaria co-cultured with SCC2 cancer cells under both bone 
resorption and formation conditions in the absence and presence of 30 µM ALN 
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doses.  The calvaria were washed twice with 1 ml of 50 mM Tris buffer, pH7.5 
and incubated in 0.5 ml of 50 mM Tris buffer, pH7.4 containing 0.5% Triton-100 
for 2 hour over ice.  The calvaria were then washed three times with 1 ml of 50 
mM Tris buffer, pH7.4 and suspended in 0.5 ml of the 50 mM Tris buffer 
containing 5% BSA and a primary human cytokeratin 7 antibody (mouse 
monoclonal [OV-TL 12/30], Abcam, Co) overnight at 4°C.  The next day, the 
primary antibody was removed and the calvaria were washed three times with 1 
ml of 50 mM Tris buffer followed by incubation with 5 µg of green-fluorescent-
tagged secondary antibody raised against mouse IgG in goat (Alexa Fluor® 488 
green dye, emission = 519nm, absorption = 495nm, Life Technology, Inc) in 0.5 
ml Tris buffer overnight at 4°C.  The calvaria were removed from the secondary 
fluorescent antibody buffer, washed three times with Tris buffer and left in 0.5 ml 
of Tris buffer.  To prepare for two-photon confocal microscopy, the calvaria were 
labeled with blue-fluorescent DAPI (4’,6-diamidino-2-phenylindole 
dihydrochloride, emission = 455nm, absorbance = 345nm, Sigma-Aldrich, Co) at 
dilution of 1:1000 and 0.4 nmol of red-fluorescent bisphosphonate (OsteoSense 
680EX, Perkin-Elmer, Inc.) for 1 hour at room temperature.  The calvaria were 
mounted on confocal microscope dishes with Vectashield mounting medium for 
Fluorescence (Vector Laboratories, Inc. Burlingame, CA 94010) and three 
fluorescent emissions (green, blue, and red) were acquired at 200X magnification 
and 5 µM intervals with total coverage of 100 µM distance for vertical scanning 
observations, and up to 180 µM distance for horizontal scanning observations 
using high resolution two-photon confocal microscope LSM 710 model.  The 
64	
acquired images were analyzed using Image J software program for generating 
merged fluorescent spatial orientation of the SCC2 cells relative to bone cells 
and the mineralized bone matrix.  The merged images were viewed in 3D 
orientation and recorded as an AVI movie to provide continuous visualization of 
the cellular characteristics as a function of different planes relative to the 
mineralized bone matrix. 
 
6.9 Statistical Analysis 
Chemical and biochemical data are presented as mean ± S.D.  The 
statistical significance of the difference between controls and different treatment 
groups were evaluated using two-tailed, paired t test with equal variance.  The 
differences between groups were considered statistically significant for p < 0.05. 
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7. Results 
7.1.  Effect of ALN Concentration on SCC2-dsRED Cells 
 The data analysis of 2D-cells co-culture of SCC2 cells with different 
concentrations of ALN in the absence or presence of ASC at time of seeding or 
confluence are presented in Figures 17-24.  In the 2D-cell culture of SCC2 cells 
in FCS media, with ALN added at time of confluence (Figure 17), ALN increased 
SCC2 detachment and decreased SCC2 attachment in a concentration-
dependent manner while there was no significant change in SCC2 cell viability. In 
the 2D-cell culture of SCC2 cells in FCS media with ASC with ALN added at time 
of confluence (Figure 18), ALN decreased total cell number and increased SCC2 
cell detachment in a concentration-dependent manner while increasing the 
percentage of dead SCC2 cells.  In the 2D-cell culture of SCC2 cells in FCS 
media with ALN added at seeding (Figure 19), there was no significant change in 
total cell number or SCC2 cell attachment, except in the groups treated with 15 
µM ALN and 30 µM ALN (p<0.05). ALN did not affect viability of overall or 
attached SCC2 cells.  However, when compared with the same experimental 
condition at time of confluence all of the groups showed higher percentage of 
dead SCC2 cells overall and lower percentage of live attached SCC2 cells.    In 
2D-cell culture of SCC2 cells in FCS media with ASC with ALN added at seeding 
(Figure 20), ALN decreased total cell number and the number of attached SCC2 
cells in a concentration-dependent manner while increasing SCC2 cell 
detachment and decreasing SCC2 cell attachment for groups treated with 15 µM 
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ALN and 30 µM ALN.  In addition, ALN significantly decreased the SCC2 viability 
except in the group treated with 1 µM ALN (p<0.05).   
 The effect of ASC & ALN in 2D-cells co-culture of SCC2 cells in media 
containing BSA instead of FCS, with ALN added in the presence or absence of 
ASC at time of seeding or confluence is show Figure 21-24. When ALN is added 
to the cell culture at time of confluence, as shown by Figure 21, ALN significantly 
increased SCC2 cells detachment in the groups treated with 15 µM ALN and 30 
µM ALN (p<0.05).  ALN also significantly decreased the SCC2 cell viability in the 
groups treated with 15 µM ALN and 30 µM ALN while had no significant effect on 
the viability of attached SCC2 cells.  Figure 22 shows data for 2D-cell cultures of 
SCC2 cells in BSA media with ASC, with ALN added at time of confluence.  ALN 
increased SCC2 cell detachment and decreased SCC2 cell attachment in a 
concentration-dependent manner. ALN also significantly decreased the SCC2 
cell viability in the groups treated with 15 µM ALN and 30 µM ALN.   Figure 23-24 
showed 2D-cells co-culture of SCC2 cells in BSA media, with ALN added in the 
presence or absence of ASC at time of seeding.  Both figures showed that SCC2 
cells do not survive well in this condition, but ALN did not affect SCC2 cells 
detachment or SCC2 cell viability.   
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Figure 17 – SCC2 2D-Cell Culture in FCS Media with ALN at Confluence.  
2D-cell cultures of SCC2 cells in FCS media in the presence or absence of ALN 
added at tim cell confluence:  (A) and (B) ALN increased total cell number and 
decreased SCC2 attachment in a concentration-dependent manner. Results are 
expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test with 
equal variance compared with Control); (C) and (D) ALN did not affect viability of 
overall or attached SCC2 cells.  
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Figure 18 – SCC2 2D-Cell Culture in FCS Media with ALN and ASC at 
Confluence.  2D-cell cultures of SCC2 cells in FCS media wit ASC in the 
presence or absence of ALN added at time of cell confluence:  (A) and (B) ALN 
decreased total cell number and increased percentage of SCC2 cells detachment 
in a concentration-dependent manner, except in the experimental group treated 
with 1 µM ALN. Results are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, 
P<0.001, Two-tailed t test with equal variance compared with Control); (C) ALN 
significantly increased percentage of dead SCC2 cells in a concentration-
dependent manner except in the group treated with 1 µM ALN.  Results are 
expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test with 
equal variance compared to Control); (D) ALN significantly decreased 
percentage of live cells in the experimental group treated with 1 µM ALN.  
Results are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-
tailed t test with equal variance compared to Control).  
 
 
 
 
 
 
73	
 
 
 
 
74	
 
 
 
 
75	
Figure 19 – SCC2 2D-Cell Culture in FCS Media with ALN at Seeding.  2D-
cell cultures of SCC2 cells in FCS media in the presence or absence of ALN 
added at seeding:  (A) and (B) There was no significant change in total cell 
number or SCC2 cell attachment, except in the groups treated with 15 µM ALN 
and 30 µM ALN. Results are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, 
P<0.001, Two-tailed t test with equal variance compared to Control); (C) and (D) 
ALN did not affect viability of overall or attached SCC2 cells.  However, when 
compared to the same experimental groups at confluence, all of the groups 
showed higher percentage of dead SCC2 cells and lower percentage of attached 
SCC2 cells.   
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Figure 20 – SCC2 2D-Cell Culture in FCS Media with ALN and ASC at 
Seeding.  2D-cell cultures of SCC2 cells in FCS media wit ASC in the presence 
and absence of ALN added at seeding: (A) ALN decreased total cell number and 
number of attached SCC2 cells in a concentration-dependent manner.   Results 
are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test 
with equal variance compared to Control); (B) ALN increased SCC2 cells 
detachment and decreased SCC2 cells attachment for groups treated with 15 µM 
ALN and 30 µM ALN.  Results are expressed as a mean ± S.D. (n=3) (*, P<0.05, 
**, P<0.001, Two-tailed t test with equal variance compared to Control); (C) ALN 
significantly decreased the SCC2 viability except in the group treated with 1 µM 
ALN.  Results are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, 
Two-tailed t test with equal variance compared to Control); (D) ALN did not affect 
the viability of attached SCC2 cells.   
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Figure 21 – SCC2 2D-Cell Culture in BSA Media with ALN at Confluence.  
2D-cell cultures of SCC2 cells in BSA media in the presence or absence of ALN 
added at cell confluence:  (A) ALN increased total cell number and SCC2 cells 
detachment in the groups treated with 15 µM ALN and 30 µM ALN.   Results are 
expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test with 
equal variance compared to Control); (C) and (D) ALN significantly decreased 
the SCC2 cell viability in the groups treated with 15 µM ALN and 30 µM ALN 
while had no significant effect on the viability of attached SCC2 cells.  Results 
are expressed as a mean ± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test 
with equal variance compared to Control).  
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Figure 22 – SCC2 2D-Cell Culture in BSA Media with ALN and ASC at 
Confluence.  2D-cell cultures of SCC2 cells in BSA media with ASC in the 
presence or absence of ALN added at time of cell confluence:  (A) and (B) ALN 
increased SCC2 cell detachment and decreased SCC2 cell attachment in a 
concentration-dependent manner.   Results are expressed as a mean ± S.D. 
(n=3) (*, P<0.05, **, P<0.001, Two-tailed t test with equal variance compared to 
Control); (C) and (D) ALN significantly decreased the overall SCC2 cell viability in 
the groups treated with 15 µM ALN and 30 µM ALN while decreasing viability of 
attached SCC2 cells treated with 30 µM ALN.   Results are expressed as a mean 
± S.D. (n=3) (*, P<0.05, **, P<0.001, Two-tailed t test with equal variance 
compared to Control). 
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Figure 23 – SCC2 2D-Cell Culture in BSA Media with ALN at Seeding.  2D-
cell cultures of SCC2 cells in BSA media in the presence or absence of ALN 
added at seeding:  (A) and (B) ALN did not affect SCC2 cells detachment or 
SCC2 cell viability among the experimental groups.  (C) Photomicrographs of 
control and each experimental group were taken at last day of experiment (20X 
magnification).  SCC2 cells do not survive well with BSA media and ALN.   
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Figure 24 – SCC2 2D-Cell Culture in BSA Media with ALN and ASC at 
Seeding.  2D-cell cultures of SCC2 cells in BSA media with ASC in the presence 
or absence of ALN added at seeding:  (A) and (B) ALN did not affect SCC2 cells 
detachment or SCC2 cell viability.  (C) Photomicrographs of control and each 
experimental group were taken at last day of experiment (20X magnification). 
SCC2 cells do not survive well with BSA media and ALN.   
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7.2.   Histologic Observations and Visualization of Osteoclastic Activity by 
Neutral Red Staining: Effect of ALN and Calvarial Cells Viability on OCs 
Formation and Bone Resorption in Bone Resorptive Model.   
 The H&E stained sections of calvaria bones in the bone resorptive models 
are illustrated in Figures 25-27.  Figure 25 (A) and (E) showed no OCs formation 
and bone resorption for calvaria control in both H&E section and NR staining. 
H&E section and NR staining for calvaria treated with 30 µM ALN, showing no 
OCs formation and bone resorption (Figure 25 (B) and (F)).  Calvaria co-cultured 
with SCC2 cells, H&E staining showed tumor cell colonization on the endosteal 
side of calvaria with areas of osteoclastic bone resorption (Figure 25 (C)) while 
NR staining of calvaria showed the presence of multinucleated OCs (MNOCs) 
(Figure 25 (G)). H&E section of parietal bone and NR staining for calvaria co-
cultured with SCC2 cells and 30 µM ALN showed SCC2 cells colonization on the 
endosteal surface with inhibition of bone resorption and no presence of MNOC 
(Figure 25 (D) and (H)).  These observations were expected since ALN inhibits 
OC proliferation and differentiation which reduces bone resorption. 
 H&E sections and NR stained calvaria for calvaria co-cultured with SCC2 
cells and ALN (Figure 26).  Calvaria co-cultured with single dosage of 0.5 µM 
ALN, H&E section of parietal bone showed SCC2 cells colonization and areas of 
osteoclastic bone resorption (Figure 26 (A)), and NR stained calvaria 
demonstrated presence of numerous MNOCs (Figure 25 (D)).  Calvaria co-
cultured with 0.5 µM ALN and 1.5 µM ALN, Figure 26 (B) & (C) and (E) & (F) 
showed similar observation for H&E sections and NR stained calvaria as the 
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calvaria co-cultured with SCC2 cells and single dose of 0.5 µM ALN.   
 H&E section for calvaria for calvaria that have been frozen and thawed 
prior to the co-culture with SCC2 cells showed reduced number of periosteal and 
endosteal cells while there was no sign of SCC2 cells colonization or osteoclastic 
bone resorption (Figure 27 (A)) and NR staining showed no presence of MNOC 
(Figure 27 (C)).  For calvaria treated with 10% formaldehyde prior to co-culture 
with SCC2 cells, H&E section illustrated fixed calvarial bone cells with no tumor 
cell colonization (Figure 27 (B)), and no presence of MNOC on the NR stained 
calvaria (Figure 27 (D)).   
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Figure 25 – Microscopic Observation for Bone Resorption Model: Control, 
Calvaria Co-culture with SCC2 Cells in the Absence and Presence of ALN. 
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Figure 26 – Microscopic Observation for Bone Resorption Model: Calvaria 
Co-culture with SCC2 Cells and Different ALN Concentrations 
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Figure 27 – Microscopic Observation for Bone Resorption Model: Calvaria 
of Reduced Viability Co-culture with SCC2 Cells 
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Figures 25-27: Histology Observation and NR Staining in the Bone 
Resorption Model: Effect of ALN on OCs Formation and Bone Resorption. 
The untreated media control, Figure 25 (A) calvaria showed no osteoclastic 
resorption, and (E) NR stained calvaria showed no resorption.  For calvaria 
treated with 30 µM ALN, Figure 25 (B) H&E section showed no osteoclastic 
resorption, (F) NR stained calvaria showed no resorption.  For calvaria co-
cultured with SCC2 cells, calvaria showed osteoclastic bone resorption (Figure 
25 (C)), with numerous multinucleated osteoclasts (MNOC) (Figure 25 (G)).  
Calvaria co-cultured with SCC2 cells and 30 µM ALN, calvaria showed partial 
osteoclastic bone resorption with most of the bone intact (Figure 25 (D)), with no 
MNOC (Figure 25 (H)).  Calvaria co-cultured with SCC2 cells and single dosage 
of 0.5 µM ALN, Figure 26 (A) showed osteoclastic bone resorption with MNOC 
(Figure 26 (D)).  Calvaria co-cultured with SCC2 cells and 0.5 µM ALN, Figure 26 
(B) showed osteoclastic bone resorption with MNOC (Figure 26 (E)).  Calvaria 
co-cultured with SCC2 cells and 1.5 µM ALN, Figure 26 (C) showed osteoclastic 
bone resorption with MNOC (Figure 26 (F)). Calvaria that have been 
frozen/thawed co-cultured with SCC2 cells, Figure 27 (A) showed no noticeable 
tumor cell colonization and no osteoclastic bone resorption with no MNOC 
(Figure 27 (C)).  Calvaria treated with 10% formaldehyde co-cultured with SCC2 
cells, Figure 27 (B) showed no tumor cells colonization and no bone resorption 
with no MNOC (Figure 27 (D)).  Magnifications: H&E x10, NR x10.   
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7.3.   Quantitative Evaluation of the Tumor Colony on Calvarial Bones and 
Cancer Cell Viability for Bone Resorptive Model  
 Quantitative analysis measured for total cell number, cells suspended in 
media, cells attached to the roller tube and cells on calvarial bone, Figures 28-30. 
There was a significant increase in total cell number, cells suspended in media 
and cells on calvarial bones for calvaria co-cultured with SCC2 cells in the 
presence and absence of ALN (Figure 28 (A)).  There was no significant 
difference for SCC2 cells cultured in FCS media and BSA media.  Figure 28 (B) 
demonstrated that there is no significant difference in cell viability between the 
control groups and calvaria co-cultured with SCC2 cells and ALN.   
 A significant decrease in total cell number and cells suspended in media 
occurred in calvaria co-cultured with 0.5 µM ALN and 1.5 µM ALN (Figure 29 
(A)). Figure 29 (B) illustrated no significant difference in cell viability between 
calvaria co-cultured with SCC2 cells and calvaria co-cultured with SCC2 cells 
and ALN. 
 Figure 30 demonstrated the analysis for co-cultures of calvaria that have 
either been frozen/thawed or treated with 10% formaldehyde prior to start of 
experiment with SCC2 cells.  Figure 30 (A) demonstrated a significant decrease 
in total cell number and cells in media for both experimental groups, while Figure 
30 (B) showed no significant difference in cell viability between calvaria co-
cultured with SCC2 cells and the experimental groups. 
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Figure 28 – Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for Bone Resorption Model: Control Groups, Calvaria Co-culture 
with SCC2 Cells in the Absence and Presence of ALN.  Quantitative analysis 
of total cell number, cells in the media, on the roller tube and calvarial bone, and 
overall cell viability.  (A) There was no significant difference between SCC2 cells 
in FCS media and BSA media.  There was a significant increase in the total cell 
number, cells suspended in media and number of cells on calvarial bone for 
calvaria co-cultured with SCC2 cells in the absence and presence of ALN.  
Results are expressed as a mean ± S.D. (*, P<0.05, **, P<0.001, Two-tailed t test 
with equal variance, compared with Calvaria); (B) There was no significant 
difference in cell viability between SCC2 cells in FCS media and BSA media, and 
in the presence and absence of ALN.   
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Figure 29 – Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for Bone Resorption Model: Calvaria Co-cultures with SCC2 Cells 
and Different ALN Concentrations.  Quantitative analysis of total cell number, 
cells in the media, on the roller tube and calvarial bone, and overall cell viability.  
(A) There was a significant decrease in the amount of cells suspended in media 
for calvaria co-cultured with 0.5 µM ALN and 1.5 µM ALN. Results are expressed 
as a mean ± S.D. (*, P<0.05, **, P<0.001, Two-tailed t test with equal variance, 
compared with calvarial co-cultured with SCC2 cells).  (B) There was no 
significant difference in cell viability between calvaria co-cultured with SCC2 cells 
and calvaria co-cultured with SCC2 cells and ALN. 
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Figure 30 – Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for Bone Resorption Model: Calvaria of Reduced Viability Co-
cultured with SCC2 Cells.  Quantitative analysis of total cell number, cells in the 
media, on the roller tube and calvarial bone, and overall cell viability.  (A) There 
was a significant decrease in the total cell number and amount of cells 
suspended in media for calvaria that have been frozen/thawed or treated with 
10% formaldehyde.  Results are expressed as a mean ± S.D. (*, P<0.05, **, 
P<0.001, Two-tailed t test with equal variance, compared with calvarial co-
cultured with SCC2 cells).  (B) There was no significant difference in cells viability 
between calvaria co-culture with SCC2 cells and the experimental groups. 
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7.4. Quantitative Analysis of Changes in Media Calcium Concentration 
and TRAP Activity: Effect of ALN and Calvarial Cells Viability on OCs 
Formation and Bone Resorption in Bone Resorptive Model.   
7.4.1  Calcium Release vs. Time 
 Calcium release of each media collected over the 8-day culture period is 
demonstrated in Figure 31.  The data represent net calcium release after 
correction with calcium concentration of media and reagent.  Figure 31 (A) shows 
calcium concentration plotted as function of time for: calvaria control, calvaria + 
30 µM ALN, calvaria co-cultured with SCC2 cells in the absence and presence of 
30 µM ALN.  Calvaria co-cultured with SCC2 cells showed substantial release of 
calcium with maximum release on day 4.  Calvaria co-cultured with SCC2 cells 
and 30 µM ALN showed a decreased calcium release.  Figure 31 (B) showed 
calcium concentration plotted as function of time for: calvaria control, calvaria co-
cultured with SCC2 cells and different concentrations of ALN.  Calvaria treated 
with single dosage of 0.5 µM ALN, 0.5 µM ALN, 1.5 µM ALN all demonstrated 
higher level of calcium release, compared to the calvaria control on day 4, with 
calvaria c-cultured with SCC2 cells + 1.5 µM ALN showing the highest level of 
calcium release.  All 3 groups showed decreased calcium release on day 6 and 
day 8, and all 3 groups have similar calcium release level on day 8.  Figure 31 
(C), calvaria control, calvaria co-cultured with SCC2 cells, SCC2 Cells + calvaria 
(Freeze/Thaw, and SCC2 cells + calvaria treated with 10% formaldehyde.  Both 
experimental groups showed lower calcium release than calvaria co-cultured with 
SCC2 cells, but calvaria (Freeze/Thaw) showed higher level of calcium release 
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than calvaria control on day 4.  Both groups experienced peak of calcium release 
on day 6, with subsequent decrease on day 8.   
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Figure 31 – Bone Resorption Model: Calcium Release Vs. Time. Calcium 
release from calvaria control, calvaria co-cultured with SCC2 cells in the 
presence and absence of 30 µM ALN (Figure 31 (A)). Calvaria co-cultured with 
SCC2 cells showed substantial release of calcium with maximum release on day 
4 of experiment.  Calvaria co-cultured with SCC2 cells and 30 µM ALN showed a 
decrease in calcium release.  In addition, the peak release of calcium was no 
longer observed which reflects the inhibitory effect of ALN on osteoclasts.  
Calvaria treated with single dosage of 0.5 µM ALN, 0.5 µM ALN, 1.5 µM ALN all 
demonstrated higher level of calcium release compared to the calvaria control on 
day 4, with calvaria co-cultured with SCC2 cells + 1.5 µM ALN showing the 
highest release of calcium (Figure 31 (B)).  All 3 groups showed decrease in 
calcium release on day 6 and day 8, and all 3 groups had similar calcium release 
level on day 8.  Figure 31 (C), SCC2 cells + calvaria (Freeze/Thaw) and SCC2 
cells + calvaria treated with 10% formaldehyde showed lower level of calcium 
release than calvaria co-cultured with SCC2 cells, but calvaria (Freeze/Thaw) 
showed higher level of calcium release than calvaria control on day 4.  Both 
groups’ calcium release peaked on day 6, with subsequent decrease on day 8. 
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7.4.2  Cumulative Calcium Release and TRAP Activity 
Total cumulative calcium release for each experimental group over the 
eight days culture period and TRAP activity are represented in Figures 32-34.  
Figure 32 (A) showed quantitative calcium analysis of media collected from 
calvaria control groups, calvaria co-cultured with SCC2 cells in the presence and 
absence of 30 µM ALN.  Comparison between calvarial control and calvaria co-
cultured with SCC2 cells showed significant increase in cumulative calcium 
release, reflecting extensive bone resorption.  Comparison between calvaria co-
culture and the inclusion of 30 µM ALN showed significant decrease in 
cumulative calcium release, reflecting reduction in bone resorption.  The data for 
cumulative calcium release are correlated with Figure 32 (B) showing significant 
increase in TRAP activity when comparing calvaria control and calvaria-cultured 
with SCC2 cells.  A significant decrease in TRAP activity occurred between 
calvaria co-cultured with SCC2 cells and calvaria-SCC2 cells co-cultured with 30 
µM ALN, and between calvaria co-cultured in the absence and presence of 30 
µM ALN.  This reflected a substantial decrease in osteoclastic bone resorption 
with the presence of ALN.  There was a significant increase in cumulative 
calcium release in calvaria co-cultured with single dosage of 0.5 µM ALN, 0.5 µM 
ALN and 1.5 µM ALN (Figure 33 (A)).  The data are correlated with TRAP activity 
in Figure 33 (B), which showed a significant increase in TRAP activity for those 3 
experimental groups.  Figure 34 (A) demonstrated no significant difference in 
calcium release between calvaria control and SCC2 cells + calvaria 
(Freeze/Thaw) and SCC2 cells + calvaria treated with 10% formaldehyde.  
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However, there is a significant difference in calcium release between these 2 
groups and calvaria co-cultured with SCC2 cells.  Calvaria treated with 10% 
formaldehyde also showed significantly lower calcium release than calvaria 
(freeze/thaw).  Figure 34 (B) illustrated significantly lower TRAP activity for SCC2 
cells + calvaria (freeze/thaw) and SCC2 cells + calvaria with 10% formaldehyde 
when compared to that of calvaria control and calvaria-SCC2 cells co-culture. 
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Figure 32 – Cumulative Calcium Release and TRAP Activity for Bone 
Resorption Model: Control Groups, Calvaria Co-culture with SCC2 Cells in 
the Absence and Presence of ALN  
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Figure 33 – Cumulative Calcium Release and TRAP Activity for Bone 
Resorption Model: Calvaria Co-culture with SCC2 Cells and Different ALN 
Concentrations 
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Figure 34 – Cumulative Calcium Release and TRAP Activity for Bone 
Resorption Model: Calvaria of Reduced Viability Co-culture with SCC2 Cells  
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Figures 32-34 – Quantitative Analysis of Cumulative Calcium Release and 
TRAP Activity for Bone Resorption Model.  Figure 32 (A), quantitative calcium 
analysis of media collected from calvaria control, calvaria + 30 µM ALN, calvaria 
co-cultured with SCC2 cells in the absence and presence of 30 µM ALN.  
Comparison between calvarial control and calvaria co-cultured with SCC2 cells 
showed significant increase in cumulative calcium release, reflecting extensive 
bone resorption.  Comparison between calvaria-SCC2 cells co-culture and the 
calvaria co-culture with SCC2 cells + 30 µM ALN showed significant decrease in 
cumulative calcium release, reflecting reduction in bone resorption.  Results are 
expressed as a mean ± S.D. (*, P<0.05, **, P<0.001, Two-tailed t test with equal 
variance compared with calvaria control).  Figure 32 (B), quantitative TRAP 
activity of media collected from calvaria control groups, calvaria + 30 µM ALN, 
calvaria co-cultured with SCC2 cells in the absence and presence of 30 µM ALN.  
There is significant increase in TRAP activity when comparing data of calvaria 
control and that of calvaria-cultured with SCC2 cells.  A significant decrease in 
TRAP activity occurred between calvaria co-cultured with SCC2 cells and 
calvaria-SCC2 cells co-culture with 30 µM ALN, and between calvaria in the 
absence and presence of 30 µM ALN.  Results are expressed as a mean ± S.D. 
(*, P<0.05, **, P<0.001, Two-tailed t test with equal variance compared with 
calvaria control).  This reflected substantial decrease in osteoclastic bone 
resorption with the presence of ALN.  Figure 33 (A), cumulative calcium release 
for calvaria control, calvaria co-cultured with SCC2 cells and different ALN 
concentrations (single dosage of 0.5 µM ALN, 0.5 µM ALN, 1.5 µM ALN and 30 
113	
µM ALN).  It illustrated significant increase in cumulative calcium release in 
calvaria co-cultured with single dosage of 0.5 µM ALN, 0.5 µM ALN and 1.5 µM 
ALN.  Figure 33 (B), TRAP activity for calvaria control, calvaria co-cultured with 
SCC2 cells and different ALN concentrations (single dosage of 0.5 µM ALN, 0.5 
µM ALN and 1.5 µM ALN), showing significant increase in TRAP activity for 
those 3 experimental groups.  Results are expressed as a mean ± S.D. (*, 
P<0.05, **, P<0.001, Two-tailed t test with equal variance compared with 
calvarial control).  Figure 34 (A) demonstrated no significant reduction in calcium 
release between calvaria control and SCC2 cells + calvaria (freeze/thaw) and 
SCC2 cells + calvaria treated with 10% formaldehyde.  However, there is 
significant reduction in calcium release between calvaria co-cultured with SCC2 
cells and SCC2 cells + calvaria (freeze/thaw) and SCC2 cells + calvaria treated 
with 10% formaldehyde.  Calvaria treated with 10% formaldehyde co-culture with 
SCC2 cells also showed significantly lower calcium release than calvaria 
(freeze/thaw) co-culture with SCC2 cells.  Results are expressed as a mean ± 
S.D. (*, P<0.05, **, P<0.001, Two-tailed t test with equal variance compared with 
calvaria control).  Figure 34 (B) illustrated significantly lower TRAP activity for 
SCC2 cells + calvaria (freeze/thaw) and SCC2 cells + calvaria treated with 10% 
formaldehyde when compared to that of calvaria control. Results are expressed 
as a mean ± S.D. (*, P<0.05, **, P<0.001, Two-tailed t test with equal variance 
compared with calvaria control).  
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7.5. Histologic Observations: Effect of ALN and Calvarial Cells Viability on 
OBs Formation and Bone Formation in ASC-Stimulated Bone Formation 
Model.   
 The histologic observations of H&E stained section of calvarial bones in the 
bone formation model are represented in Figures 35-37.  Figure 35 (A) showed 
H&E section of calvaria ASC control with new osteoid formation while Figure 35 
(B) showed H&E section of calvaria + ASC + 30 µM ALN with no sign of 
osteoblast differentiation or osteoid formation.  Figure 35 (C) illustrated calvaria 
co-cultured with SCC2 cells + ASC, showing OB differentiation and new osteoid 
formation instead of bone resorption.  H&E section of calvaria co-cultured with 
SCC2 cells + ASC + 30 µM ALN is displayed on Figure 35 (D), showing no sign 
of bone formation or resorption.  The NR staining of all the above experimental 
groups, as displayed in Figure 35 (E)-(H) respectively, demonstrated absence of 
MNOC which confirmed with the histologic observations. 
 Figure 36 (A)–(C) showed H&E sections of calvaria cultured with SCC2 
cells + ASC + different concentration of ALN.  New osteoid formation is noted in 
calvaria treated with 0.5 µM ALN and 1.5 µM ALN, which is illustrated in Figure 
36 (B) and (C).  No presence of MNOC is noted in the NR staining of all three 
experimental groups, as shown in Figure 36 (D) – (F).   
 The H&E sections of calvaria that have been frozen/thawed co-cultured 
with ASC and SCC2 cells, and calvaria that were treated with 10% formaldehyde 
co-cultured with ASC and SCC2 cells are displayed in Figure 37 (A) and (B), 
respectively.  No new osteoid formation is noted for both groups.  Calvaria that 
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were frozen/thawed showed reduced number of periosteal and endosteal cells, 
and no nuclei were noted for the existing osteocytes.  Calvaria that were treated 
with 10% formaldehyde showed fixed periosteal cells, endosteal cells and 
osteocytes.   Figure 37 (C) and (D) demonstrated NR staining for both 
experimental groups respectively with absence of MNOC for both groups.   
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Figure 35 – Microscopic Observation for ASC-Stimulated Bone Formation 
Model: Control, Calvaria Co-culture with SCC2 Cells in the Absence and 
Presence of ALN. 
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Figure 36 – Microscopic Observation for ASC-Stimulated Bone Formation 
Model: Calvaria Co-culture with SCC2 Cells and Different ALN 
Concentrations 
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Figure 37 –Microscopic Observation for ASC-Stimulated Bone Formation 
Model: Calvaria od Reduced Viability Co-culture with SCC2 Cells 
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Figures 35-37 – Histologic Observation, NR Staining in the ASC Stimulated 
Bone Formation Model.  ASC-stimulated control with new osteoid formation 
(Figure 35 (A)), while calvaria with ASC + 30 µM ALN showined no sign of bone 
formation or bone resorption (Figure 35 (B)).  Calvaria co-cultured with SCC2 
cells + ASC showed cancer cells colonization on the endosteal side of bone and 
new osteoid formation (Figure 35 (C)).  Calvaria co-cultured with SCC2 + ASC + 
30 µM ALN, showed tumor cells colonization and no sign of bone formation or 
bone resorption (Figure 35 (D)).  NR stained calvaria of ASC control, calvaria 
with ASC + 30 µM ALN, calvaria co-cultured with SCC2 cells + ASC, and calvaria 
co-cultured with SCC2 cells + ASC + 30 µM ALN all showed absence of MNOC 
(Figure 35 (E)-(H)), confirming the observation made for the histologic sections. 
Calvaria co-cultured with SCC2 cells + ASC + one dosage 0.5 µM ALN showed 
no sign of bone resorption or formation (Figure 36 (A)).  Calvaria co-cultured with 
SCC2 cells + ASC + 0.5 µM ALN showed tumor cells colonization on endosteal 
surface and no new osteoid formation (Figure 36 (B)).  Calvaria co-cultured with 
SCC2 cells + ASC + 1.5 µM ALN showing tumor cells colonization on endosteal 
surface and no new osteoid formation (Figure 36 (C)).  NR stained calvaria of 
calvaria co-culture with SCC2 cells + one dosage 0.5 µM ALN, calvaria co-
cultured with SCC2 cells + ASC + 0.5 µM ALN, and calvaria co-cultured with 
SCC2 cells + ASC + 1.5 µM ALN all showed absence of MNOC (Figure 36 (D)-
(F)), confirming observations made with histologic sections.  Calvaria that have 
been frozen/thawed prior to start of experiment co-cultured with SCC2 cells 
showed no new osteoid formation (Figure 37 (A)).  Calvaria treated with 10% 
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formaldehyde co-cultured with SCC2 cells showed no tumor cell colonization and 
no sign of bone formation (Figure 37 (B)).  NR stained calvaria of the 
experimental groups mentioned above, respectively, illustrating absence of 
MNOC (Figure 37 (C) and (D)).  Magnifications: H&E x10, NR x20. 
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7.6. Quantitative Evaluation of the Tumor Colony on Calvarial Bones and 
Cancer Cell Viability for ASC-Stimulated Bone Formation Model 
Quantitative analysis of total cell number, number of cells suspended in 
media, number of cells attached to roller tube, and number of colonized cells on 
calvaria along with quantitative analysis of cancer cell viability for the bone 
formation model are displayed in Figures 38-40. SCC2 cells in BSA media + ASC 
had significantly lower number of cells attached to roller tube (p<0.05) (Figure 38 
(A)).  When compared with calvaria ASC control, calvaria co-cultured with SCC2 
cells + ASC + 30 µM ALN showed significant increase in total cell number 
(p<0.001), number of cells suspended in media (p<0.05), and cells colonized on 
calvaria (p<0.001) (Figure 38 (A)).  No significant difference in cell viability was 
noted between calvaria control and the different experimental groups (Figure 38 
(B)).   
Figure 39 (A) illustrated no significant difference in the quantitative analysis 
of total cell number, number of cells suspended in media, number of cells 
attached to roller tube, and number of colonized cells on calvaria between 
calvaria control and the different experimental groups.  Quantitative analysis of 
cell viability showed calvaria co-cultured with SCC2 cells + ASC + single dosage 
of 0.5 µM ALN and calvaria co-cultured with SCC2 cells + ASC + 1.5 µM ALN 
demonstrated higher percentage of live cells and lower percentage of dead cells 
(p<0.05 for single dosage of 0.5 µM ALN; p<0.001 for 1.5 µM ALN), as shown in 
Figure 39 (B). 
 Figure 40 (A) illustrated that when quantitative analysis for tumor colony 
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for calvaria co-cultured with ASC and SCC2 are compared with that of SCC2 
cells + calvaria (freeze/thaw), and SCC2 cells + calvaria treated with 10% 
formaldehyde, both experimental groups showed significant decrease in amount 
of cells suspended in media and amount of colonized cells on calvaria (p<0.05). 
Figure 40 (B) showed that calvaria treated with 10% formaldehyde co-cultured 
with ASC and SCC2 cells demonstrated significant decrease in percentage of 
live cells and increase in percentage of dead cells (p<0.05 for live cells, p<0.001 
for dead cells). 
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Figure 38 - Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for ASC-Stimulated Bone Formation Model: Control Groups, 
Calvaria Co-culture with SCC2 Cells in the Absence and Presence of ALN.  
Quantitative analysis of total cell number, amount of cells in the media, on the 
roller tube and calvarial bone, and overall cell viability.  (A) SCC2 cells in BSA 
media had significantly lower number of cells attached to roller tube.  When 
compared with calvaria ASC control, calvaria co-cultured with SCC2 cells + ASC 
+ 30 µM ALN showed significant increase in total cell number, number of cells 
suspended in media, and cells on calvaria.  Results are expressed as a mean ± 
S.D. (*, p<0.05, **, p<0.001, Two-tailed t test with equal variance compared with 
calvaria ASC control); (B) There is no significant difference in cell viability 
between SCC2 cells in FCS media and BSA media, and no significant difference 
in cell viability between the calvaria ASC control and calvaria co-cultured with 
SCC2 cells + ASC in the absence and presence of ALN.   
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Figure 39 - Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for ASC-Stimulated Bone Formation Model: Calvaria Co-culture 
with SCC2 Cells and Different ALN Concentrations.  Quantitative analysis of 
total cell number, amount of cells in the media, on the roller tube and calvarial 
bone, and overall cell viability.  (A) When quantitative evaluation for calvaria co-
cultured with SCC2 cells + ASC are compared with that of calvaria co-cultured 
with SCC2 cells + ASC and different ALN concentrations (single dosage of 0.5 
µM ALN, 0.5 µM ALN, 1.5 µM ALN and 30 µM ALN), there is no statistical 
significance in total cell number, number of cells in media, number of cells on 
roller tube, or number of cells on calvaria.  (B) Percentage of live and dead cells 
for calvaria co-cultured with SCC2 cells + ASC and different ALN concentrations 
(single dosage of 0.5 µM ALN, 0.5 µM ALN, 1.5 µM ALN and 30 µM ALN).  
Calvaria co-cultured with SCC2 cells + ASC + single dosage of 0.5 µM AL and 
calvaria co-cultured with SCC2 cells + ASC + 1.5 µM ALN showed increase in 
percentage of live cells and decrease in percentage of dead cells.  Results are 
expressed as a mean ± S.D. (*, p<0.05, **, p<0.001, Two-tailed t test with equal 
variance compared with calvaria co-cultured with SCC2 cells + ASC). 
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Figure 40 - Quantitative Evaluation of the Tumor Colony and Cancer Cell 
Viability for ASC-Stimulated Bone Formation Model: Calvaria of Reduced 
Viability Co-cultures with SCC2 Cells.  (A) Calvaria (freeze/thaw) co-cultured 
with ASC and SCC2 and calvaria treated with 10% formaldehyde co-cultured 
with SCC2 cells showed significant decrease in amount of cells suspended in 
media and amount of colonized cells on calvaria compared to calvaria co-
cultured with SCC2 + ASC. Results are expressed as a mean ± S.D. (*, p<0.05, 
Two-tailed t test with equal variance compared with calvaria co-cultured with 
SCC2 cells + ASC).  (B) Calvaria treated with 10% formaldehyde co-cultured with 
ASC and SCC2 cells demonstrated a significant decrease in percentage of live 
cells and increase in percentage of dead cells.  Results are expressed as a mean 
± S.D. (*, p<0.05, **, p<0.001, Two-tailed t test with equal variance, compared 
with calvaria co-cultured with SCC2 cells + ASC). 
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7.7. Quantitative Analysis of Changes in Media Calcium Concentration 
and ALP Activity: Effect of ALN and SCC2 Cells Viability on OBs Formation 
and Bone Formation in Bone Formation Model.   
7.7.1. Calcium Uptake Vs. Time 
Calcium uptake of each media over the 8-day culture period for the bone 
formation model is represented in Figure 41.  Similar to the resorption model, 
media were collected on day 2, 4, 6 and 8 during the culture period.  The data 
represented were corrected for media concentration to obtain net calcium uptake 
and presented as nmol calcium/10ul media. Calvaria control and calvaria co-
cultured with SCC2 have similar calcium concentration throughout the 
experiment, with the maximum value on day 6.  Calvaria + ASC demonstrated an 
increase in calcium concentration from day 4 to day 8.  Calvaria + ASC + 30 µM 
ALN have the lowest calcium concentration out of all the experimental groups, 
suggesting a decrease in calcium release (Figure 41 (A)).   
Calvaria co-cultured with SCC2 cells + ASC + single dosage of 0.5 µM 
ALN, 0.5 µM ALN and 1.5 µM ALN all demonstrated higher calcium 
concentration than the calvaria control throughout the entire experiment.  All 3 
experimental groups experienced a decrease in calcium concentration level from 
day 6 to day 8, suggesting bone formation between day 6 and day 8 (Figure 41 
(B)).  
Calvaria (freeze/thaw) co-cultured with SCC2 cells + ASC, and calvaria 
treated with 10% formaldehyde co-cultured with SCC2 cells + ASC showed 
calcium concentration level lower than calvaria control with gradual increase of 
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calcium release that peaked on day 6 of experiment, and decreased between 
day 6 and day 8 (Figure 41 (C)). 
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Figure 41 - Bone Formation Model: Calcium Uptake Vs. Time.  Calcium 
concentration in collected media plotted as a function of time in the bone 
formation model. Calvaria control and calvaria co-cultured with SCC2 cells + 
ASC have similar calcium concentrations throughout the experiment; both groups 
experienced a slight increase in calcium release between day 4 and day 6, and 
decrease in calcium concentration between day 6 and day 8.  Calvaria + ASC 
showed increase in calcium concentration between day 4 and 8, suggesting bone 
formation during day 2 and 4.  Calvaria + ASC + 30 µM ALN showed substantial 
decrease in calcium concentration between day 4 and day 6, with gradual 
increase in calcium release between day 6 and 8.  Calvaria co-cultured with 
SCC2 cells + ASC + 30 µM ALN demonstrated a gradual decrease in calcium 
concentration throughout the experiment (Figure 41 (A)).  Calvaria co-cultured 
with SCC2 cells + ASC + single dosage of 0.5 µM ALN, 0.5 µM ALN and 1.5 µM 
ALN all demonstrated higher calcium concentration than the calvaria control 
throughout the entire experiment.  All 3 experimental groups experienced a 
decrease in calcium concentration level from day 6 to day 8, suggesting bone 
formation between day 6 and day 8 (Figure 41 (B)). Calvaria (freeze/thaw) and 
calvaria (10% formaldehyde) both showed calcium concentration level lower than 
calvaria control throughout the experiment.  Both groups demonstrated an 
increase in calcium release between day 4 to day 6, with decrease in calcium 
concentration between day 6 to day 8 (Figure 41 (C)). 
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7.7.2. Cumulative Calcium Uptake & ALP Activity 
Total cumulative calcium uptake and ALP activity for each experimental 
group over the 8 day culture period for the bone formation model are represented 
in Figures 42-44.  Surprisingly calvaria + ASC + 30 µM ALN showed decreased 
calcium release and significant increase in ALP activity (p<0.001) (Figure 42 (A) 
and (B)).  Calvaria co-cultured with SCC2 cells + ASC demonstrated an increase 
in cumulative calcium concentration and showed a significant decrease in ALP 
activity (p<0.001).  A significant decrease of cumulative calcium concentration 
was noted between calvaria co-culture with SCC2 cells + ASC and calvaria co-
cultured with SCC2 cells + ASC + 30 µM ALN, but both experimental groups 
demonstrated similar ALP activity level (Figure 42 (A) and (B)).  Calvaria co-
cultured with SCC2 cells + ASC + different ALN concentrations (single dosage of 
0.5  µM ALN, 0.5  µM ALN, 1.5  µM ALN) all showed significantly increased 
calcium release (p<0.05) and significantly decreased ALP activity (p<0.05 for 
single dosage of 0.5  µM ALN and 0.5  µM ALN; p<0.001 for 1.5  µM ALN), 
(Figure 43 (A) and (B)).  Calvaria (freeze/thaw) co-cultured with ASC and SCC2 
cells and calvaria (10% formaldehyde) co-culture with SCC2 cells + ASC both 
showed reduced calcium release, and calvaria treated with10% formaldehyde 
have significant lower calcium concentration when compared with that of calvaria 
(freeze/thaw) (p<0.05) (Figure 44 (A)). Figure 44 (B) demonstrated significant 
decrease in ALP activity for both calvaria (10% formaldehy) (p<0.001) and 
calvaria (freeze/thaw) (p<0.05). 
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Figure 42 – Cumulative Calcium Uptake and ALP Activity for ASC-
Stimulated Bone Formation Model: Control Groups, Calvaria Co-culture 
with SCC2 Cells in the Absence and Presence of ALN  
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Figure 43 – Cumulative Calcium Uptake and ALP Activity for ASC-
Stimulated Bone Formation Model: Calvaria Co-culture with SCC2 Cells and 
Different ALN Concentrations 
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Figure 44 – Cumulative Calcium Uptake and ALP Activity for ASC-
Stimulated Bone Formation Model: Calvaria of Reduced Viability Co-culture 
with SCC2 Cells 
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Figures 42-44 – Quantitative Analysis of Cumulative Calcium Uptake and 
ALP Activity for ASC-Stimulated Bone Formation Model.  When compared to 
calvaria control, calvaria + ASC +  30 µM ALN  and calvaria co-cultured with 
SCC2 cells + ASC + 30 µM ALN  showed significantly decreased calcium 
release.  Results are expressed as a mean ± S.D. (*, p<0.05; **, p<0.001, Two-
tailed t test with equal variance, compared with calvaria control). Also, there is 
significant decrease is cumulative calcium concentration between calvaria co-
cultured with SCC2 cells + ASC with and without 30 µM ALN ((Figure 42 (A)). 
Calvaria + ASC + 30 µM ALN showed increased ALP activity when compared to 
the calvarial control, while calvaria co-cultured with SCC2 cells + ASC, and 
calvaria co-cultured with SCC2 cells + ASC + 30 µM ALN showed significantly 
decreased ALP activity (Figure 42 (B)).  Results are expressed as a mean ± S.D. 
(**, p<0.001, Two-tailed t test with equal variance, compared with calvaria 
control).  Cumulative calcium release significantly increased in calvaria co-
cultured with SCC2 cells + ASC and single dosage of 0.5 µM ALN, 0.5 µM ALN 
and 1.5 µM ALN, with significant decrease in calcium release for calvaria co-
cultured with SCC2 cells and 30 µM ALN (Figure 43 (A)).  Results are expressed 
as a mean ± S.D. (*, p<0.05; **, p<0.001, Two-tailed t test with equal variance 
compared with calvaria control). ALP activity for calvaria co-cultured with SCC2 
cells + ASC and different ALN concentrations (single dosage of 0.5 µM ALN, 0.5 
µM ALN, 1.5 µM ALN and 30 µM ALN) showed significant decrease in ALP 
activity for calvaria co-cultured with SCC2 cells + ASC and single dosage of 0.5 
µM ALN, 0.5 µM ALN and 1.5 µM ALN (Figure 43 (B)).  Results are expressed as 
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a mean ± S.D. (*, p<0.05, **, p<0.001, Two-tailed t test with equal variance 
compared with calvarial control).  Cumulative calcium uptake for calvaria control, 
calvaria co-cultured with ASC and SCC2 cells, calvaria that have been 
frozen/thawed co-cultured with ASC, calvaria treated with 10% formaldehyde co-
culture with SCC2 cells + ASC.  Both experimental groups showed significant 
reduction in calcium release, and calvaria treated with 10% formaldehyde have 
significant lower calcium concentration when compared with that of calvaria 
(freeze/thaw) (Figure 44 (A)).  Results are expressed as a mean ± S.D. (*, 
p<0.05, **, p<0.001, Two-tailed t test with equal variance, compared with calvaria 
control).  ALP activity significantly decreased for calvaria (freeze/thaw) co-
cultured with ASC and SCC2 cells and calvaria treated with 10% formaldehyde 
co-cultured with ASC and SCC2 cells (Figure 44 (B)).  Results are expressed as 
a mean ± S.D.  (**, p<0.001, Two-tailed t test with equal variance compared with 
calvaria control).   
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7.8. High Resolution 2-Photon Confocal Microscopy for Both Bone 
Resorption Model and ASC-Stimulated Bone Formation Model 
 High-resolution 2-photon confocal microscopy was utilized for 3D 
visualization of cancer-bone interaction between SCC2 cells and the calvaria.  
Different fluorescent labels were used to distinguish the mineralized bone matrix, 
bone cells and SCC2 cells: red-fluorescent BP for the mineralized bone matrix, 
green-fluorescent human cytokeratin-7 for SCC2 cells and blue-fluorescent DAPI 
for cell nuclei.  Vertical and horizontal recorder of the calvarial ones were 
performed for both the bone resorption and bone formation model with the 
horizontal recording captured from endosteum and moving toward the 
periosteum over a depth of 175 µm at 5 µm intervals with 200x magnification.  
After the recording, 3D composites of the bone resorption and bone formation 
model were generated using the ImageJ software and are displayed in Figure 45 
(A)-(L).  Both the bone resorption and bone formation model showed tumor cell 
colonization with separation from the mineralized bone matrix by the endosteal 
cells.  No tumor cells were seen on the bone surface in the 3D vertical view in 
Figure 45 (F) and (I).  For the calvaria-cultured with SCC2 cells in the bone 
resorption model, as in Figure 45 (A)-(C), tumor cells appeared oval in shape and 
formed a 3-dimensional structure with multiple layers of tumor cells when 
colonizing the endosteal side of calvaria.  Figure 45 (B) showed mineralized bone 
matrix in red, with endosteal cells as small oval blue nuclei, and tumor cells as 
larger blue nuclei surrounded by green fluorescence.  Distinct bone resorption 
areas are noted with loss of mineralized bone matrix.  Figure (D)-(F) showed 
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calvaria co-cultured with SCC2 cells + ASC in the bone formation model.  Under 
this condition, the SCC2 cells appeared different morphologically as the cells 
became more elongated with extended cellular processes.  Calvaria co-cultured 
with SCC2 cells + ALN are displayed in Figure 45 (G)-(I).  SCC2 cells appeared 
ovoid in shapes, and absence of OC-bone resorption area is absent.  However, 
in the presence of ALN, the osteocytes appeared to lose their nuclei and showed 
degeneration of the mineralized bone matrix.  Figure 45 (J)-(L) showed calvaria 
co-cultured with SCC2 cells + ASC + ALN.  Under the formation conditions, 
SCC2 cells also displayed cellular elongation independent of the presence of 
ALN.  Also, loss of osteocyte nuclei can also be noted in Figure 45 (K) under the 
bone formation model.   
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Figure 45 – High Resolution 2-Photon Confocal Microscopy for Both Bone 
Resorption Model and Bone Formation Model 
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Figure 45 – High Resolution 2-Photon Confocal Microscopy for Both Bone 
Resorption Model and Bone Formation Model (Continued) 
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Figure 45 – High Resolution 2-Photon Confocal Microscopy for Both Bone 
Resorption Model and Bone Formation Model.  2-photon high-resolution 
microscopy of calvaria co-cultured with SCC2 cells under bone formation and 
bone resorption conditions in the absence and presence of ALN.  (A)-(C), 
composite of calvaria co-cultured with SCC2 cells in bone resorption model, fixed 
in formalin and fluorescent labeled with red-fluorescent BP for the mineralized 
bone matrix, green-fluorescent human cytokeratin-7 for SCC2 cells and blue-
fluorescent DAPI for cell nuclei.  (A), fluorescent composite of BP, human 
cytokeratin-7 and DAPI of horizontal recording, showing 3D structure of SCC2 
cells.  (B), fluorescent composite of BP, human cytokeratin-7 and DAPI of 
horizontal recording, showing endosteal cells separating SCC2 cells from 
mineralized bone, and presence of OC bone resorption.  (C) 90°side view of the 
3D orientation of the cancer cells-bone interactions.  (D)-(F), composite of 
calvaria co-cultured with SCC2 cells + ASC in bone formation condition, fixed in 
formalin and fluorescent labeled with red-fluorescent BP for the mineralized bone 
matrix, green-fluorescent human cytokeratin-7 for SCC2 cells and blue-
fluorescent DAPI for cell nuclei.  (D), fluorescent composite of BP, human 
cytokeratin-7 and DAPI of horizontal recording, showing 3D structure of SCC2 
cells.  (E), fluorescent composite of BP, human cytokeratin-7 and DAPI of 
horizontal recording, showing spatial relationship between SCC2 cells, endosteal 
cells and the mineralized bone matrix.  (F), 90°side view of the 3D orientation of 
the cancer cells-bone interactions.  (G)-(I), composite of calvaria co-cultured with 
SCC2 cells + ALN in bone resorption condition, fixed in formalin and fluorescent 
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labeled with red-fluorescent BP for the mineralized bone matrix, green-
fluorescent human cytokeratin-7 for SCC2 cells and blue-fluorescent DAPI for 
cell nuclei.  (G), fluorescent composite of BP, human cytokeratin-7 and DAPI of 
horizontal recording, showing 3D structure of SCC2 cells.  (H), fluorescent 
composite of BP, human cytokeratin-7 and DAPI of horizontal recording, showing 
loss of osteocyte nuclei and deterioration of mineralized bone matrix.  (I),Partial 
side view of 3D orientation of the cancer cells-bone interactions.  (J)-(L), 
composite of calvaria co-cultured with SCC2 cells + ALN+ ASC in bone 
resorption condition, fixed in formalin and fluorescent labeled with red-fluorescent 
BP for the mineralized bone matrix, green-fluorescent human cytokeratin-7 for 
SCC2 cells and blue-fluorescent DAPI for cell nuclei.  (J), fluorescent composite 
of BP, human cytokeratin-7 and DAPI of horizontal recording, showing 3D 
structure of SCC2 cells.  (K), fluorescent composite of BP, human cytokeratin-7 
and DAPI of horizontal recording, showing loss of osteocyte nuclei and 
deterioration of mineralized bone matrix.  (L), Partial side view of 3D orientation 
of the cancer cells-bone interactions.   
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8. Discussion 
Bone is a dynamic and highly vascularized organ that provides an ideal 
microenvironment for sustaining cancer cells, fostering cancer cell colonization 
and drug therapy resistance.  Bone resorption induced by cancer cell metastasis 
can release growth factor from the bone matrix that are essential for fostering 
metastasis development by facilitating proliferation of dormant cancer cells.   
Over time, the goal of cancer therapy has been shifting from targeting and killing 
the cancer cells directly to interfering with mechanisms that support cancer cell 
survival. More than 100 years ago, Stephen Paget proposed the seed-and-soil 
hypothesis, which suggested that modifying the microenvironment that support 
cancer cell growth may be a valuable approach of treating cancer cells 
metastasis (Gnant & Clezardin, 2012).   
Based on the concept that cancer-bone metastasis and cancer cell 
survival are bone resorption-dependent, bisphosphonates (BPs) has been used 
clinically as an adjunctive anti-cancer medication due to its effect on reducing 
cancer cells-induced bone resorption and cancer cells survival.  In pre-clinical 
trials, nitrogen-containing bisphosphonate (NBPs) demonstrated anticancer 
activity by inhibiting the activity of farnesyl diphosphate (FPP) synthase of the 
mevalonate pathway causing impairment in cancer cell adhesion, migration, and 
proliferation.  Alendronate, clodronate and zoledronic acid have also been found 
to inhibit cancer cell growth and induce cancer cell apoptosis (Gnant & Clezardin, 
2012).   
The aim of this study was to determine the effect of ALN on SCC2 cells, 
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calvarial bone biology, and the interplay between the SCC2 cells and calvarial 
bone.  The results of the 2D SCC2 cells culture demonstrated that when SCC2 
cells were cultured alone, ALN interfered with SCC2 cells attachment to the cell 
culture dish in a dose-dependent manner.  Also, increasing ALN concentration 
resulted in an increase of percentage of dead SCC2 cells in the presence of ASC 
and BSA in cell-culture media.  It should also be noted that when ALN was added 
to cell-culture media with BSA at seeding, SCC2 cells were not able to attach to 
the cell-culture dish and proliferate.  The results of these studies corresponded to 
the finding of Donetti in 2014, which stated that ALN affects epithelial cells 
adhesion and proliferation by decreasing reducing desmoglein 1 and keratin 10 
expression and changing morphology of the desmosomes (Donetti et al, 2014).  
The increased effect of ALN on SCC2 viability in the presence of ASC and BSA 
in cell-culture media can be explained by the importance of FCS in cell-
maintenance (Hemeda et al, 2014) and the anti-cancer effect of ASC that was 
discovered by Pires et al in 2016, whose study showed ASC can induce anti-
proliferative and cytotoxic effect on three colon cancer cell lines, and that ASC 
can induce cell death through oxidative stress (Pires et al, 2016).   
The present study provided multiple insights into the nature of cancer 
cells-bone interaction.  First of all, the result demonstrated that cancer cells-bone 
metastasis is not dependent on osteoclast-mediated bone resorption.  Through 
histologic study, it was apparent that exposure of live calvarial bone to SCC2 
cancer cells led to cancer cells colonization on the calvarial endosteal surface, 
and subsequent activation of the osteoclast-mediated bone resorption.  In 
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addition, calvaria co-cultured with SCC2 cells and ALN resulted in cancer cells 
colonization in the presence of reduced bone resorption.  Furthermore, in the 
ASC-induced bone formation model new osteoid formation was activated and 
cancer cell colonization on calvarial endosteal surface was noted despite the 
absence of osteoclastic bone resorption.  The above observations lead to the 
conclusion that SCC2 cells do not depend on osteoclastic bone resorption for 
cancer-bone metastasis to occur. 
 The difference between the 2D cancer cell-culture and the 3D roller tube 
calvaria-cancer cell co-culture also demonstrated bone-mediated resistance of 
SCC2 cancer cells to ALN therapy.  In the absence of calvarial bone addition of 
30 µM ALN led to significant increase of SCC2 cell detachment from the cell-
culture dish and percentage of dead SCC2 cells in the presence of BSA and ASC 
in cell-culture media.  However, because of ALN’s high affinity to mineralized 
tissue, there is no difference in the number of SCC2 cells attached to calvaria 
bone in the presence and absence of 30 µM ALN, and there is no significant 
difference in SCC2 cells viability in the presence and absence of ALN and ASC, 
even though the calvaria-SCC2 cells co-cultured was carried out in media 
containing BSA.    Our results are in contrast to the results of other studies that 
showed NBP able to reduce tumor burden on bone and decrease cancer cells 
metastasis (Daubine et al, 2007), and varied from the belief that cancer cells 
require osteoclast-mediated bone resorption to release bone-derived growth 
factors in order to survive in bone (Clezardin, 2011). 
 The result from the resorption model showed that calvaria co-cultured with 
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SCC2 cells resulted in significant increase in cumulative calcium release and 
TRAP enzyme activity, a marker for osteoclast activity, compared to calvaria 
alone.  These observations also corresponded to the histologic study and NR 
staining showing multinucleated osteoclasts and osteoclast-mediated bone 
resorption.  When calvaria was co-cultured with SCC2 cells and 30 µM ALN, 
significant decreases in cumulative calcium release and TRAP activity were 
observed compared with calvaria co-cultured with SCC2 cells along with absence 
of multinucleated osteoclast on the NR staining and reduced bone resorption on 
the histologic study.  These results clearly demonstrate and are consistent with 
various studies which have suggested that addition of ALN can decrease the 
number and resorptive activity of OCs and inhibit differentiation of osteoclastic 
lineage cells (Clezardin, 2013; Liu, 2014).  When calvaria were co-cultured with 
SCC2 cells and smaller dosage of ALN (single dosage 0.5 µM, 0.5 µM or 1.5 
µM), no significant difference in cumulative calcium release and TRAP activity 
was noted compared to calvaria co-cultured with SCC2 cells.  This result was 
consistent with NR staining and histologic study which showed multinucleated 
osteoclasts and bone resorption.  This is consistent with a previous study 
(Daubine et al, 2007), which showed that a single dose of zoledronic acid and 
dosage lower than clinical dosage had no significant effect on bone destruction 
caused by cancer cell metastasis.     
 In the formation model when calvaria was co-cultured with SCC2 cells in 
the presence of ASC new bone formation was noted on the histologic study, 
corresponding to a significant decrease in cumulative calcium release and an 
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increase in ALP activity.  On the other hand, when calvaria was co-cultured with 
SCC2 cells and 30 µM ALN in the presence of ASC, the bone was unable to 
undergo osteoblast differentiation as no new osteoid formation was noted on the 
histologic study, and a decrease in ALP activity was noted compared to calvaria 
+ ASC alone.   Similarly, co-culture of calvaria with SCC2 cells and lower dosage 
of ALN (single dosage 0.5 µM, 0.5 µM or 1.5 µM) in the presence of ASC showed 
histologically no new osteoid formation.  This was accompanied with significant 
increase in cumulative calcium release for all three groups along with decrease in 
ALP activity compared to calvaria control.  The results of this experiment were 
consistent with previous study from this laboratory (Alasmari et al, 2016), which 
showed that bone treated with ALN was unable to undergo new bone formation 
in the presence of ASC.  Importantly, the present study using SCC2 cells instead 
of prostate (PC3) and breast (MDA-231) cancer cells also demonstrated that 
simultaneous co-culture of calvaria + SCC2 cells + ALN in the presence and 
absence of ASC that inhibition of osteoclastic bone resorption is achieved at the 
stage of OC differentiation.  In the formation model it is evident from the 2-photon 
confocal microscopy images that ALN elicited degeneration of osteocytes when 
calvaria are stimulated to undergo OB differentiation and new osteoid formation.  
Therefore, ALN’s regulation of OC at the differentiation level resulted in impaired 
function of OB and osteocytes which are responsible for synthesis of RANKL that 
is essential for the differentiation of macrophages to OCs.   
 The current study in addition also investigated the phenomenon of whether 
cancer-bone interaction and bone colonization was dependent on live bone and 
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bone lining cell layers.  The impact of devitalizing bone and bone cells was 
evaluated by subjecting the bone to formaldehyde fixation and/or repeat freezing 
approaches.  Formaldehyde is commonly used as tissue fixative by cross-linking 
amino groups in proteins with nearby nitrogen atoms while freezing and thawing 
calvarial bone would induce osteocytes, osteoblasts and bone lining fibroblasts to 
burst and die.  On the histologic photomicrograph, calvaria co-cultured with 
SCC2 cells in the presence and absence of ASC showed reduced number of 
periosteal and endosteal cells, and majority of osteocytes present did not have 
nuclei present.  Such bone organs co-cultured with cancer cells showed no 
cancer cell colonization neither in resorption nor formation model system, 
indicating that dead bone can not support cancer cell attachment, colonization 
and growth.  This observation corresponded to the decreased in cumulative 
calcium release and TRAP/ALP activity as bone resorption was reduced due to 
lack of cancer cells colonization as a result of reduce calvarial cells viability.  
When bone treated with 10% formaldehyde was co-cultured with SCC2 cells in 
the presence and absence of ASC histologic study showed intact osteocyte 
nuclei and preserved periosteal and endosteal cells.  But similar to bone that has 
been frozen/thawed no cancer cell colonization was noted in the resorption or 
formation model. Decrease in cumulative calcium release and TRAP activity was 
noted in the resorption model, while a significant decrease in calcium release 
was noted in the formation model with decrease in ALP activity.  This decrease in 
cumulative calcium release in the bone formation model may be due to increased 
mineral deposition of the hydroxyapatite in the presence of the protein-
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crosslinking caused by the formaldehyde treatment.  Observations from both 
experimental groups suggested that bone with reduced viability would not be 
able to support cancer cells therefore cancer cells metastasis to bone would be 
affected negatively in the presence of bone injury, bone toxicity and bone cell-
death.   
 Some limitations of the experiment include small sample size and short 
culture period.  Certain experimental groups in this study only contain three or 
four samples; therefore increasing sample size in the future may ensure 
consistency in the result and accuracy in the statistical analysis.  Extending the 
culture period may allow us to investigate the long-term effect of ALN has on 
SCC2 cells, calvarial bone and the calvaria-SCC2 cell interaction.  Future 
direction of our study will continue with investigation of other BPs’ and their 
impact on SCC2 cells and cancer-bone cells interactions.   
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